Eli Lilly and (LLY) 10-Q 30 Oct 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 19, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	Lilly Eli & Co
Entity Central Index Key	59,478
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,108,076,549

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue	$ 4,959.7	$ 4,875.6	$ 14,583.1	$ 14,494.3
Costs, expenses, and other:
Cost of sales	1,236.9	1,267	3,648	3,679.4
Research and development	1,143.4	1,243.2	3,352.2	3,547.9
Marketing, selling, and administrative	1,575.7	1,672.1	4,734.6	4,820.9
Acquired in-process research and development	0	95	336	95
Asset impairment, restructuring, and other special charges	42.4	36.3	222.8	67.7
Other - net, (income) expense	(86.5)	(93.5)	(55.9)	(203.3)
Cost of sales, operating expenses, and other-net	3,911.9	4,220.1	12,237.7	12,007.6
Income before income taxes	1,047.8	655.5	2,345.4	2,486.7
Income taxes	248.1	154.9	415.4	524.7
Net income	$ 799.7	$ 500.6	$ 1,930	$ 1,962
Earnings per share:
Basic	$ 0.75	$ 0.47	$ 1.82	$ 1.83
Diluted	$ 0.75	$ 0.47	$ 1.81	$ 1.82
Shares used in calculation of earnings per share:
Basic	1,061.4	1,069.6	1,062.4	1,071.4
Diluted	1,065.2	1,074.4	1,066	1,075.7
Dividends paid per share	$ 0.50	$ 0.49	$ 1.50	$ 1.47

Consolidated Condensed Stateme3

Consolidated Condensed Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Net income	$ 799.7	$ 500.6	$ 1,930	$ 1,962
Other comprehensive loss, net of tax	(263.8)	(616.3)	(675.2)	(548.9)
Comprehensive income (loss)	$ 535.9	$ (115.7)	$ 1,254.8	$ 1,413.1

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 3,238.8	$ 3,871.6
Short-term investments	1,080.4	955.4
Accounts receivable, net of allowances of $47.8 (2015) and $55.0 (2014)	3,401.9	3,234.6
Other receivables	665.8	566.7
Inventories	3,417.7	2,740
Prepaid expenses and other	762.4	811.5
Total current assets	12,567	12,179.8
Other Assets
Restricted cash	0	5,405.6
Investments	4,102	4,568.9
Goodwill	4,054.9	1,758.1
Other intangibles, net	4,615.9	2,884.2
Sundry	2,889.6	2,382.8
Total other assets	15,662.4	16,999.6
Property and Equipment
Land, buildings, equipment, and construction in progress	16,611.5	16,029.3
Accumulated depreciation	(8,536.2)	(8,065.4)
Property and equipment, net	8,075.3	7,963.9
Total assets	36,304.7	37,143.3
Current Liabilities
Short-term borrowings and current maturities of long-term debt	9.3	2,688.7
Accounts payable	1,179.3	1,128.1
Employee compensation	829.6	759
Sales rebates and discounts	2,541.8	2,068.8
Dividends payable	0	530.3
Income taxes payable	700	93.5
Deferred income taxes	943.6	1,466.5
Other current liabilities	2,099.7	2,472.6
Total current liabilities	8,303.3	11,207.5
Other Liabilities
Long-term debt	8,069.6	5,332.8
Accrued retirement benefits	2,358.2	2,562.9
Long-term income taxes payable	910.6	998.5
Other noncurrent liabilities	1,422.1	1,653.5
Total other liabilities	12,760.5	10,547.7
Eli Lilly and Company Shareholders' Equity
Common stock	693	694.6
Additional paid-in capital	5,441.9	5,292.3
Retained earnings	16,856.7	16,482.7
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss	(4,667)	(3,991.8)
Cost of common stock in treasury	(90)	(91.4)
Total Eli Lilly and Company shareholders' equity	15,221.4	15,373.2
Noncontrolling interests	19.5	14.9
Total equity	15,240.9	15,388.1
Total liabilities and equity	$ 36,304.7	$ 37,143.3

Consolidated Condensed Balance5

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Allowances for doubtful accounts	$ 47.8	$ 55

Consolidated Condensed Stateme6

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows from Operating Activities
Net income	$ 1,930	$ 1,962
Adjustments to Reconcile Net Income to Cash Flows from Operating Activities:
Depreciation and amortization	1,084.3	1,039.6
Change in deferred income taxes	(671)	151.9
Debt extinguishment loss	166.7	0
Stock-based compensation expense	159.4	115.4
Net proceeds (payments) for terminations of interest rate swaps	(186.1)	252.5
Acquired in-process research and development	336	95
Other changes in operating assets and liabilities, net of acquisitions and divestitures	(660.1)	(548.3)
Other non-cash operating activities, net	(190.7)	(50.6)
Net Cash Provided by Operating Activities	1,968.5	3,017.5
Cash Flows from Investing Activities
Net purchases of property and equipment	(686)	(753.8)
Proceeds from sales and maturities of short-term investments	1,585.8	2,661.6
Purchases of short-term investments	(764.2)	(1,401.8)
Proceeds from sales of noncurrent investments	2,271.8	7,355.5
Purchases of noncurrent investments	(2,673.4)	(8,636.7)
Restricted cash released for acquisition	5,405.6	0
Cash paid for acquisitions, net of cash acquired	(5,287.8)	(551.4)
Proceeds from sale of product rights	410	0
Purchase of in-process research and development	(386)	(45)
Other investing activities, net	(102.7)	(358.6)
Net Cash Used for Investing Activities	(226.9)	(1,730.2)
Cash Flows from Financing Activities
Dividends paid	(1,594)	(1,576)
Net change in short-term borrowings	(2,680.7)	304.9
Proceeds from issuance of long-term debt	4,454.6	992.9
Repayment of long-term debt	(1,950.6)	(1,034.3)
Purchases of common stock	(496.6)	(500)
Other financing activities, net	27.7	109
Net Cash Used for Financing Activities	(2,239.6)	(1,703.5)
Effect of exchange rate changes on cash and cash equivalents	(134.8)	(248.2)
Net decrease in cash and cash equivalents	(632.8)	(664.4)
Cash and cash equivalents at January 1	3,871.6	3,830.2
Cash and Cash Equivalents at September 30	$ 3,238.8	$ 3,165.8

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation [Text Block]	Note 1: Basis of Presentation We have prepared the accompanying unaudited consolidated condensed financial statements in accordance with the requirements of Form 10-Q and, therefore, they do not include all information and footnotes necessary for a fair presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States (GAAP). In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for a fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2014. We issued our financial statements by filing with the Securities and Exchange Commission and have evaluated subsequent events up to the time of the filing. Certain reclassifications have been made to prior periods in the consolidated condensed financial statements and accompanying notes to conform with the current presentation. All per-share amounts, unless otherwise noted in the footnotes, are presented on a diluted basis, that is, based on the weighted-average number of outstanding common shares plus the effect of incremental shares from our stock-based compensation programs.

Implementation of New Financial

Implementation of New Financial Accounting Pronouncements	9 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Accounting Changes and Error Corrections [Text Block]	Note 2: Implementation of New Financial Accounting Pronouncements The following table provides a brief description of an accounting standard that has not yet been adopted that could have a material effect on our financial statements: Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2014-09, Revenue from Contracts with Customers This standard will replace existing revenue recognition standards and will require entities to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. In August 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2015-14, Revenue from Contracts with Customers , which deferred the effective date of the new revenue recognition standard by one year (to January 1, 2018 for us), but permits entities to adopt the new standard on the original effective date if they choose. We are evaluating our anticipated date of adoption. There are areas within the standard that are currently under review and reconsideration by the FASB, which could lead to updates to the standard. As the outcomes of this review and reconsideration could lead to significant changes to the standard, we are still in the process of determining our approach to the adoption of the standard, as well as the anticipated impact to our consolidated financial statements.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisitions [Text Block]	Note 3: Acquisitions During 2015 and 2014, we completed the acquisitions of Novartis Animal Health (Novartis AH) and Lohmann SE (Lohmann AH), respectively. These acquisitions were accounted for as business combinations under the acquisition method of accounting. The assets acquired and liabilities assumed were recorded at their respective fair values as of the acquisition date in our consolidated financial statements. The determination of estimated fair value required management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our consolidated condensed financial statements from the date of acquisition. Additionally, on October 1, 2015, Bristol-Myers Squibb Company and E.R. Squibb (collectively, BMS) transferred to us their commercialization rights with respect to Erbitux ® in the United States (U.S.) and Canada (collectively, North America) through a modification of our existing arrangement. This will be accounted for as a business combination under the acquisition method of accounting discussed above. See Note 4 for additional information related to the Erbitux arrangement. In addition to the acquisitions of businesses, we also acquired assets in development in 2015 and 2014, which are further discussed in this note below in Product and Other Acquisitions. Upon acquisition, the acquired in-process research and development (IPR&D) related to these products was immediately written off as an expense because the products had no alternative future use. For the three months ended September 30, 2015 , we recorded no acquired IPR&D charges. For the nine months ended September 30, 2015 , we recorded acquired IPR&D charges of $336.0 million , associated with these transactions and the upfront fee of $200.0 million related to tanezumab. See Note 4 for additional information related to the tanezumab arrangement. There were acquired IPR&D charges of $95.0 million for the three and nine months ended September 30, 2014 associated with these transactions. In October 2015, we acquired the worldwide rights to Locemia Solutions' intranasal glucagon, a glucagon nasal powder being investigated for the treatment for severe hypoglycemia. Upon entry into the agreement, we paid approximately $150 million , which will be accounted for in the fourth quarter of 2015. Acquisition of Businesses Novartis AH Acquisition Overview of Transaction On January 1, 2015, we acquired from Novartis AG all of the shares of certain Novartis subsidiaries and the assets and liabilities of other Novartis subsidiaries that are exclusively related to the Novartis AH business in an all-cash transaction for a total purchase price of $5.28 billion , subject to certain contractual adjustments which should be completed by December 31, 2015. As of December 31, 2014, there was $5.41 billion of cash held in escrow for the pending acquisition of Novartis AH. This cash was classified as restricted cash, a noncurrent asset, on our consolidated condensed balance sheet. As a condition to the clearance of the transaction under the Hart-Scott-Rodino Antitrust Improvements Act, following the closing of the acquisition of Novartis AH, we divested certain animal health assets in the U.S. related to the Sentinel ® canine parasiticide franchise to Virbac Corporation (Virbac) for approximately $410 million . The acquired Novartis AH business consists of the research and development, manufacture, marketing, sale and distribution of veterinary products to prevent and treat diseases in pets, farm animals, and farmed fish. Under the terms of the agreement, we acquired manufacturing sites, research and development facilities, a global commercial infrastructure and portfolio of products, a pipeline of projects in development, and employees. Assets Acquired and Liabilities Assumed Our access to Novartis AH information was limited prior to the acquisition. As a consequence, we are in the process of determining the fair values and tax bases of a significant portion of the assets acquired and liabilities assumed, including the identification and valuation of intangible assets, inventory, property and equipment, accrued expenses, and tax exposures. The final determination of these amounts will be completed as soon as possible but no later than one year from the acquisition date. The final determination may result in asset and liability fair values and tax bases that differ from the preliminary estimates and require changes to the preliminary amounts recognized. The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 1, 2015 Inventories $ 380.2 Acquired in-process research and development 295.0 Marketed products (1) 1,940.0 Property and equipment 218.9 Assets held for sale (primarily the U.S. Sentinel rights) 422.7 Accrued retirement benefits (167.6 ) Deferred income taxes (57.4 ) Other assets and liabilities - net (38.9 ) Total identifiable net assets 2,992.9 Goodwill (2) 2,290.2 Total consideration transferred - net of cash acquired $ 5,283.1 (1) These intangible assets, which will be amortized to cost of sales on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 19 years . (2) The goodwill recognized from this acquisition is attributable primarily to expected synergies that we believe will result from combining the operations of Novartis AH with our legacy Animal Health operations, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $950 million of the goodwill associated with this acquisition is estimated to be deductible for tax purposes. Actual and Supplemental Pro Forma Information Our consolidated condensed statement of operations for the three and nine months ended September 30, 2015 includes Novartis AH revenue of $255.5 million and $760.0 million , respectively. Novartis AH has been partially integrated into our animal health segment and as a result of these integration efforts, certain parts of the animal health business are operating on a combined basis, and we cannot distinguish the operations between Novartis AH and our legacy animal health business. The following unaudited pro forma financial information presents the combined consolidated results of our operations with Novartis AH as if the portion of Novartis AH that we retained after the sale to Virbac had been acquired as of January 1, 2014. We have adjusted the historical consolidated financial information to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition at the beginning of 2014. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company. Unaudited Pro Forma Consolidated Results Three Months Ended Nine Months Ended 2015 2014 2015 2014 Revenue $ 4,959.7 $ 5,151.0 $ 14,583.1 $ 15,297.1 Net income 815.0 452.8 2,039.6 1,723.7 Diluted earnings per share 0.77 0.42 1.91 1.60 The unaudited pro forma financial information above reflects primarily the following pro forma pre-tax adjustments: • Additional amortization expense of approximately $26 million and $78 million for the three and nine months ended September 30, 2014 , respectively, related to the fair value of identifiable intangible assets acquired. • Additional cost of sales in 2014, and a corresponding reduction in cost of sales in 2015, of approximately $21 million and $153 million related to the fair value adjustments to acquisition date inventory that has been sold in the three and nine months ended September 30, 2015 , respectively. • A decrease to pro forma net income of approximately $31 million and $82 million in the three and nine months ended September 30, 2014 , respectively, associated with an increase to interest expense related to the incremental debt that we issued to partially finance the acquisition and a reduction of interest income associated with investments which would have been used to partially fund the acquisition. In addition, all of the above adjustments were adjusted for the applicable tax impact. The taxes associated with the adjustments above reflect the statutory tax rates in the various jurisdictions where the fair value adjustments occurred. Lohmann AH Acquisition On April 30, 2014, we acquired Lohmann AH, a privately-held company headquartered in Cuxhaven, Germany, through a stock purchase for a total purchase price of $591.2 million , comprised of $551.4 million of net cash plus $39.8 million of assumed debt. Lohmann AH is a global leader in poultry vaccines. As part of this transaction, we acquired the rights to a range of vaccines, commercial capabilities, and manufacturing sites in Germany and the United States. The acquisition is not material to our consolidated financial statements. The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at April 30, 2014 Marketed products $ 275.4 Other intangible assets 23.9 Property and equipment 81.9 Deferred income taxes (92.7 ) Other assets and liabilities - net 51.1 Total identifiable net assets 339.6 Goodwill (1) 251.6 Total consideration transferred - net of cash acquired $ 591.2 (1) Goodwill associated with this acquisition is not deductible for tax purposes. Product and Other Acquisitions The following table summarizes our product and other acquisitions which are discussed in detail below: Counterparty Compound(s) or Therapy Acquisition Month Phase of Development (1) Acquired IPR&D Expense Innovent Biologics, Inc. (Innovent) Monoclonal antibody targeting protein CD-20 Immuno-oncology molecules cMet monoclonal antibody March 2015 Pre-clinical (2) $ 56.0 Hanmi Pharmaceutical Co., Ltd. (Hanmi) BTK Inhibitor - HM71224 April 2015 Phase I 50.0 BioNTech AG (BioNTech) Cancer immunotherapies May 2015 Pre-clinical 30.0 Immunocore Limited (Immunocore) T cell-based cancer therapies July 2014 Pre-clinical 45.0 AstraZeneca UK Limited (AstraZeneca) Oral beta-secretase cleaving enzyme inhibitor - AZD3293 September 2014 Phase I 50.0 (1) The phase of development presented is as of the date of the arrangement. (2) Prior to acquisition, Innovent's monoclonal antibody targeting protein CD-20 had received investigational new drug approval in China to begin Phase I development. In connection with the arrangements described below, our partners may be entitled to future royalties based on sales should these products be approved for commercialization and/or milestones based on the successful progress of the drug candidate through the development process. Our collaboration agreement with Innovent is to develop and commercialize a portfolio of cancer treatments. In China, we will be responsible for the commercialization efforts, while Innovent will lead the development and manufacturing efforts. Innovent also has co-promotion rights in China. We will be responsible for development, manufacturing, and commercialization efforts of Innovent's pre-clinical immuno-oncology molecules outside of China. Separate from the collaboration, we will continue the development of our cMet monoclonal antibody gene outside of China. Our collaboration agreement with Hanmi is to develop and commercialize Hanmi's compound being investigated for the treatment of autoimmune and other diseases. We received rights to the molecule for all indications on a worldwide basis excluding China, Hong Kong, Taiwan, and Korea. We will be responsible for leading development, regulatory, manufacturing, and commercial efforts in our territories. Our research collaboration with BioNTech is to discover novel cancer immunotherapies. Our co-discovery and co-development collaboration with Immunocore is to research and potentially develop pre-clinical novel T cell-based cancer therapies. Our collaboration agreement with AstraZeneca is for the worldwide co-development and co-commercialization of AstraZeneca’s compound being investigated for the potential treatment of Alzheimer’s disease. We will be responsible for leading development efforts, while AstraZeneca will be responsible for manufacturing efforts. If successful, both parties will take joint responsibility for commercialization of AZD3293. Under the agreement, both parties will share equally in the ongoing development costs, gross margins and certain other costs associated with the commercialization of the compound.

Collaborations

Collaborations	9 Months Ended
	Sep. 30, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborations [Text Block]	Note 4: Collaborations and Other Arrangements We often enter into collaborative and other similar arrangements to develop and commercialize drug candidates. Collaborative activities may include research and development, marketing and selling (including promotional activities and physician detailing), manufacturing, and distribution. These arrangements often require milestone and royalty or profit-share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements or payments to the collaboration partner. Elements within a collaboration are separated into individual units of accounting if they have standalone value from other elements within the arrangement. In these situations, the arrangement consideration is allocated to the elements on a relative selling price basis. Revenues related to products we sell pursuant to these arrangements are included in net product revenues, while other sources of revenue (e.g., royalties and profit-sharing due from our partner) are included in collaboration and other revenue. The following table summarizes our collaboration and other revenue recognized: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Collaboration and other revenue $ 215.2 $ 204.0 $ 644.7 $ 593.9 Operating expenses for costs incurred pursuant to these arrangements are reported in their respective expense line item, net of any payments due to or reimbursements due from our collaboration partners, with such reimbursements being recognized at the time the party becomes obligated to pay. Each collaboration is unique in nature, and our more significant arrangements are discussed below. Diabetes Collaboration We and Boehringer Ingelheim have a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. Currently, the compounds included in the collaboration are Boehringer Ingelheim’s two oral diabetes agents, linagliptin (trade name Trajenta ® ) and empagliflozin (trade name Jardiance ® ), and our new insulin glargine product (trade name Basaglar ® ). The table below summarizes significant regulatory and commercialization events and milestones (received) paid for the compounds included in this collaboration: Product Status Milestones (Earned) Expensed (1) Milestones (Deferred) Capitalized (2) Product Family U.S. Europe Japan Year Amount Year Amount Trajenta (3) Launched 2011 Launched 2011 Launched 2011 2015 $ — 2015 $ — 2014 — 2014 — 2013 — 2013 — Cumulative (6) 446.4 Jardiance (4) Launched 2014 Launched 2014 Launched 2015 2015 — 2015 — 2014 — 2014 299.5 2013 97.2 2013 — Cumulative (6) 299.5 Basaglar Tentatively Approved (5) Launched 2015 Launched 2015 2015 — 2015 — 2014 — 2014 (62.5 ) 2013 (50.0 ) 2013 — Cumulative (6) (62.5 ) (1) Milestones earned for Basaglar as a result of regulatory submissions were recorded as income in other-net, (income) expense. Milestones expensed for Jardiance as a result of regulatory submissions were recorded as research and development expenses. (2) In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In the future, we will be eligible to receive up to $187.5 million in success-based regulatory milestones on Basaglar. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales. (3) Jentadueto ® is included in the Trajenta family of product results. (4) Glyxambi ® and Synjardy ® are included in the Jardiance family of product results. (5) Basaglar received tentative approval in the U.S. in August 2014. The U.S. Food and Drug Administration (FDA) has determined that Basaglar meets all regulatory requirements for approval, but final approval was subject to a delay of up to 30 months as a result of patent infringement litigation filed by Sanofi-Aventis U.S. LLC (Sanofi), which markets Lantus ® (insulin glargine). In September 2015, we entered into a settlement agreement to resolve the patent litigation with Sanofi. As part of the agreement and pending FDA approval, Basaglar can be launched in the U.S. beginning on December 15, 2016. (6) The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration. In October 2014, we and Boehringer Ingelheim agreed upon certain changes to the operational and financial structure of our diabetes collaboration. Under the revised agreement the companies have continued their co-promotion work in 17 countries, representing over 90 percent of the collaboration’s anticipated market opportunity. In the other countries, the companies exclusively commercialize the respective molecules they brought to the collaboration. The modifications became effective at the end of 2014 and changed the financial terms related to the modified countries; however, the financial impact resulting from the revised terms of the agreement in these countries has not been and is not anticipated to be material. As a result of these changes, we recorded a gain of $92.0 million in 2014 related to the transfer to Boehringer Ingelheim of our license rights to co-promote linagliptin and empagliflozin in these countries, which was recorded as income in other–net, (income) expense. We also incurred a charge of $55.2 million related to the transfer to us of Boehringer Ingelheim's rights to co-promote Basaglar in countries where it is not yet approved, which was recorded as acquired IPR&D expense. With the exception of the countries affected by the amendment to the collaboration agreement, the companies share equally the ongoing development costs, commercialization costs and gross margin for any product resulting from the collaboration. We record our portion of the gross margin associated with Boehringer Ingelheim's compounds as collaboration and other revenue. We record our sales of Basaglar to third parties as net product revenues with the payments made to Boehringer Ingelheim for their portion of the gross margin recorded as cost of sales. For all compounds under this collaboration, we record our portion of the commercialization costs as marketing, selling, and administrative expense. Each company will also be entitled to potential performance payments on sales of the molecules they contribute to the collaboration. The following table summarizes our revenue recognized with respect to the Trajenta family of products: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Collaboration and other revenue $ 92.7 $ 78.9 $ 255.0 $ 246.1 Our revenues related to the Jardiance family of products and Basaglar were not significant for the three and nine months ended September 30, 2015 . Erbitux We have several collaborations with respect to Erbitux. The most significant collaborations are in the U.S., Canada, and Japan (Bristol-Myers Squibb Company); and worldwide except North America (Merck KGaA). Certain rights to Erbitux outside North America will remain with Merck KGaA (Merck) upon expiration of that agreement. The following table summarizes our revenue recognized with respect to Erbitux: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Net product revenues $ (2.3 ) $ 8.8 $ 22.6 $ 34.5 Collaboration and other revenue 88.2 84.1 286.2 242.8 Revenue $ 85.9 $ 92.9 $ 308.8 $ 277.3 Bristol-Myers Squibb Company Pursuant to commercial agreements with BMS, we have been co-developing Erbitux in North America with BMS exclusively. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. On October 1, 2015, BMS transferred their commercialization rights to us with respect to Erbitux in North America pursuant to a modification of our existing arrangement. This modification did not affect our rights with respect to Erbitux in other jurisdictions. In connection with the modification of terms, we will provide consideration to BMS based upon a tiered percentage of net sales of Erbitux in North America estimated to average 38 percent through September 2018. The transfer of the commercialization rights will be accounted for as an acquisition of a business. As a result, we will record the fair value of the commercialization rights as a marketed product asset and the fair value of the contingent consideration as a liability. The marketed product asset will be amortized to cost of sales using the straight-line method through the co-development period in North America, as set forth in the original agreement, which was scheduled to expire in September 2018. We are in the process of determining the fair values of the assets acquired and liabilities assumed. Our preliminary estimates are as follows: marketed product assets, approximately $550 million ; inventory, approximately $50 million ; goodwill, approximately $50 million ; and contingent consideration liability, approximately $650 million . The final determination of these amounts may result in asset and liability fair values that differ from the preliminary estimates. Including the Erbitux business as if we had acquired it on January 1, 2015, our combined consolidated revenue would have been approximately $14.8 billion for the nine months ended September 30, 2015 . There would have been no material change to our consolidated net income. Until the effective date of the transfer of the business, the arrangements between us and BMS, were as set forth in this paragraph. Erbitux research and development and other costs were shared by both companies according to a predetermined ratio. Responsibilities associated with clinical and other ongoing studies were apportioned between the parties under the agreements. Collaborative reimbursements due to us for supply of clinical trial materials; for research and development; and for a portion of marketing, selling, and administrative expenses were recorded as a reduction to the respective expense line items on the consolidated statement of operations. We received a distribution fee in the form of a royalty from BMS, based on a percentage of net sales in North America, which was recorded in collaboration and other revenue. Royalties due to third parties were recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties. We were responsible for the manufacture and supply of all requirements of Erbitux in bulk-form active pharmaceutical ingredient (API) for clinical and commercial use in North America, and BMS purchased all of its requirements of API from us, subject to certain stipulations per the agreement. Sales of Erbitux API to BMS were reported in net product revenues. Merck KGaA A development and license agreement grants Merck exclusive rights to market Erbitux outside of North America until December 2018. A separate agreement grants co-exclusive rights among Merck, BMS, and us in Japan and expires in 2032. This agreement was amended in 2015 to grant Merck exclusive commercialization rights in Japan but did not result in any changes to our rights. Merck manufactures Erbitux for supply in its territory as well as for Japan. We receive a royalty on the sales of Erbitux outside of North America, which is included in collaboration and other revenue as earned. Royalties due to third parties are recorded as a reduction of collaboration and other revenue, net of any royalty reimbursements due from third parties. Effient ® We are in a collaborative arrangement with Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) to develop, market, and promote Effient. We and Daiichi Sankyo co-promote Effient in certain territories (including the U.S. and five major European markets), while we have exclusive marketing rights in certain other territories. Daiichi Sankyo has exclusive marketing rights in Japan and certain other territories. The parties share approximately 50 /50 in the profits, as well as in the costs of development and marketing in the co-promotion territories. Beginning January 1, 2016, we will cease co-promotion efforts for Effient in the major European markets, and Daiichi Sankyo will exclusively promote Effient in the major European markets; however, the economic results for these countries will continue to be shared in the same proportion as they are currently. A third party manufactures bulk product, and we produce the finished product for our exclusive and co-promotion territories. We will also continue to produce the finished product for the major European markets subsequent to January 1, 2016. We record net product revenues in our exclusive and co-promotion territories. In our exclusive territories, we pay Daiichi Sankyo a royalty specific to these territories. Profit-share payments due to Daiichi Sankyo are recorded as marketing, selling, and administrative expenses. Subsequent to January 1, 2016, any profit-share payments due to us from Daiichi Sankyo for the major European markets will be recorded as collaboration and other revenue. All royalties due to Daiichi Sankyo and the third-party manufacturer are recorded in cost of sales. The following table summarizes our revenue recognized with respect to Effient: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Revenue $ 132.1 $ 131.5 $ 382.7 $ 384.4 Solanezumab We have an agreement with an affiliate of TPG-Axon Capital (TPG) whereby TPG funded a portion of the Phase III development of solanezumab. Under the agreement, TPG’s obligation to fund solanezumab costs ended in 2011. In exchange for its funding, TPG may receive success-based sales milestones totaling approximately $70 million and mid-single digit royalties contingent upon the successful development of solanezumab. The royalties would be paid for approximately 10 years after launch of a product. Baricitinib We have a worldwide license and collaboration agreement with Incyte Corporation (Incyte) which provides us the development and commercialization rights to its Janus tyrosine kinase inhibitor compound, now known as baricitinib, and certain follow-on compounds, for the treatment of inflammatory and autoimmune diseases. Incyte has the right to receive tiered, double-digit royalty payments on future global sales with rates ranging up to 20 percent if the product is successfully commercialized. The agreement provides Incyte with options to co-develop these compounds on an indication-by-indication basis by funding 30 percent of the associated development costs from the initiation of a Phase IIb trial through regulatory approval in exchange for increased tiered royalties ranging up to percentages in the high twenties. In 2010, Incyte exercised its option to co-develop baricitinib in rheumatoid arthritis. The agreement also provides Incyte with an option to co-promote in the U.S. and calls for payments associated with certain development, success-based regulatory, and sales-based milestones. As of September 30, 2015 , Incyte is eligible to receive up to $415.0 million of additional payments from us contingent upon certain development and success-based regulatory milestones as well as an additional $150.0 million of potential sales-based milestones. Tanezumab In October 2013, we entered into a collaboration agreement with Pfizer Inc. (Pfizer) to jointly develop and globally commercialize tanezumab for the treatment of osteoarthritis pain, chronic low back pain and cancer pain. Under the agreement, the companies share equally the ongoing development costs and, if successful, in gross margins and certain commercialization expenses. Following the FDA's decision in March 2015 to lift the partial clinical hold on tanezumab, Phase III trials resumed beginning in July 2015. Upon the FDA's lifting of the partial clinical hold and the decision to continue the collaboration with Pfizer, we paid an upfront fee of $200.0 million , which was expensed as acquired IPR&D in the first quarter of 2015 . In addition to this fee, we may pay up to $350.0 million in success-based regulatory milestones and up to $1.23 billion in a series of sales-based milestones, contingent upon the commercial success of tanezumab. Both parties have the right to terminate the agreement under certain circumstances. Exenatide In November 2011, we agreed with Amylin Pharmaceuticals, Inc. (Amylin) to terminate our collaborative arrangement for the joint development, marketing, and selling of Byetta ® (exenatide injection) and other forms of exenatide such as Bydureon ® (exenatide extended-release for injectable suspension). Under the terms of the termination agreement, Amylin made a one-time, upfront payment to us of $250.0 million and agreed to make other payments. Upon completion of the acquisition of Amylin by Bristol-Myers Squibb Company in August 2012, Amylin's obligation of $1.26 billion was paid in full. We would also receive a $150.0 million milestone payment contingent upon FDA approval of a once-monthly suspension version of exenatide. Commercial operations were transferred to Amylin in the U.S. in late 2011. Outside the U.S., we transferred to Amylin exenatide commercial rights and control in all markets during the first quarter of 2013. All income allocated to the business outside the U.S. that was transferred during the first quarter of 2013 was recognized as a gain on the disposition of a business in other–net, (income) expense, net of the goodwill allocated to the business transferred. Under the terms of our prior arrangement, we reported as net product revenues 100 percent of sales outside the U.S. We paid Amylin a percentage of the gross margin of exenatide sales outside of the U.S., and these costs were recorded in cost of sales. This arrangement for the commercial operations outside the U.S. continued until those rights were transferred to Amylin during the first quarter of 2013. Our net product revenues from exenatide were not significant in 2014. We have not recorded any additional revenues from exenatide in 2015 and will not do so in future periods. Summary of Commission and Profit-Share Payments The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described above: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Marketing, selling, and administrative $ 53.6 $ 53.5 $ 156.5 $ 155.4

Asset Impairment, Restructuring

Asset Impairment, Restructuring, and Other Special Charges Asset Impairment, Restructuring, and Other Special Charges	9 Months Ended
	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Activities Disclosure [Text Block]	Note 5: Asset Impairment, Restructuring, and Other Special Charges The following table summarizes the components of the recognized charges included in asset impairment, restructuring, and other special charges by segment: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Severance: Human pharmaceutical $ 9.6 $ 17.1 $ 26.5 $ 36.5 Animal health 2.5 — 38.8 — Total severance 12.1 17.1 65.3 36.5 Asset impairment and other special charges: Human pharmaceutical 0.9 2.7 18.0 14.7 Animal health 29.4 16.5 139.5 16.5 Asset impairment and other special charges 30.3 19.2 157.5 31.2 Asset impairment, restructuring, and other special charges $ 42.4 $ 36.3 $ 222.8 $ 67.7 Severance costs recognized during the three and nine months ended September 30, 2015 related primarily to the integration of Novartis AH as well as actions taken to reduce our cost structure. Substantially all of the severance costs recognized during the three and nine months ended September 30, 2014 were related to actions taken to reduce our cost structure. Asset impairment and other special charges recognized during the three and nine months ended September 30, 2015 related primarily to integration costs. The asset impairment and other special charges recognized during the nine months ended September 30, 2015 also related to intangible asset impairments due to product rationalization resulting from our acquisition of Novartis AH. Asset impairment and other special charges recognized during the three months ended September 30, 2014 consisted primarily of integration costs from our acquisition of Novartis AH. Asset impairment and other special charges recognized during the nine months ended September 30, 2014 included both integration costs resulting from our then pending acquisition of Novartis AH, as well as costs associated with the closure of a manufacturing plant.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Financial Instruments [Text Block]	Note 6: Financial Instruments Financial instruments that potentially subject us to credit risk consist principally of trade receivables and interest-bearing investments. Wholesale distributors of life-sciences products account for a substantial portion of trade receivables; collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures and insurance. A large portion of our cash is held by a few major financial institutions. We monitor our exposures with these institutions and do not expect any of these institutions to fail to meet their obligations. Major financial institutions represent the largest component of our investments in corporate debt securities. In accordance with documented corporate policies, we monitor the amount of credit exposure to any one financial institution or corporate issuer. We are exposed to credit-related losses in the event of nonperformance by counterparties to risk-management instruments but do not expect any counterparties to fail to meet their obligations given their high credit ratings. Accounting Policy for Risk-Management Instruments Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2015 , we had outstanding foreign currency forward commitments to purchase 1.08 billion U.S. dollars and sell 956.5 million euro, commitments to purchase 1.06 billion euro and sell 1.19 billion U.S. dollars, commitments to purchase 501.3 million U.S. dollars and sell 60.15 billion Japanese yen, commitments to purchase 79.2 million British pounds and sell 107.9 million euro, and commitments to purchase 289.2 million U.S. dollars and sell 187.7 million British pounds, which will all settle within 30 days . Foreign currency exchange risk is also managed through the use of foreign currency debt. Our euro-denominated notes issued in June 2015, which have a carrying amount of $2.32 billion as of September 30, 2015 , have been designated as, and are effective as, economic hedges of net investments in certain of our euro-denominated foreign operations. Accordingly, foreign currency translation gains or losses due to spot rate fluctuations on the euro-denominated notes are included as a component of other comprehensive income (loss). During the three and nine months ended September 30, 2015 , we recorded pretax foreign currency translation losses from the euro-denominated notes of $16.8 million and $50.6 million , respectively. In the normal course of business, our operations are exposed to fluctuations in interest rates which can vary the costs of financing, investing, and operating. We address a portion of these risks through a controlled program of risk management that includes the use of derivative financial instruments. The objective of controlling these risks is to limit the impact of fluctuations in interest rates on earnings. Our primary interest-rate risk exposure results from changes in short-term U.S. dollar interest rates. In an effort to manage interest-rate exposures, we strive to achieve an acceptable balance between fixed- and floating-rate debt and investment positions and may enter into interest rate swaps or collars to help maintain that balance. Interest rate swaps or collars that convert our fixed-rate debt to a floating rate are designated as fair value hedges of the underlying instruments. Interest rate swaps or collars that convert floating-rate debt to a fixed rate are designated as cash flow hedges. Interest expense on the debt is adjusted to include the payments made or received under the swap agreements. Cash proceeds from or payments to counterparties resulting from the termination of interest rate swaps are classified as operating activities in our consolidated condensed statement of cash flows. At September 30, 2015 , substantially all of our total long-term debt is at a fixed rate. We have converted approximately 40 percent of our long-term fixed-rate notes to floating rates through the use of interest rate swaps. We may enter into forward contracts and designate them as cash flow hedges to limit the potential volatility of earnings and cash flow associated with forecasted sales of available-for-sale securities. In March 2015, we issued $600.0 million of 1.25 percent fixed-rate notes due March 1, 2018, $800.0 million of 2.75 percent fixed-rate notes due June 1, 2025, and $800.0 million of 3.70 percent fixed-rate notes due March 1, 2045 with interest to be paid semi-annually. The proceeds from the issuance of the notes were used primarily to repay outstanding commercial paper issued in connection with our January 2015 acquisition of Novartis AH. In June 2015, we issued euro-denominated notes consisting of €600.0 million of 1.00 percent fixed-rate notes due June 2, 2022, €750.0 million of 1.63 percent fixed-rate notes due June 2, 2026, and €750.0 million of 2.13 percent fixed-rate notes due June 3, 2030 with interest to be paid annually. The net cash proceeds of the offering of $2.27 billion were used primarily to purchase and redeem certain higher interest rate U.S. dollar-denominated notes and to repay outstanding commercial paper. We paid $1.95 billion to purchase and redeem notes with an aggregate principal amount of $1.65 billion and a net carrying value of $1.78 billion in June 2015, resulting in a pretax debt extinguishment loss of $166.7 million , which was included in other–net, (income) expense in our consolidated condensed statement of operations during the nine months ended September 30, 2015 . We may enter into forward-starting interest rate swaps, which we designate as cash flow hedges, as part of any anticipated future debt issuances in order to reduce the risk of cash flow volatility from future changes in interest rates. Upon completion of a debt issuance and termination of the swap, the change in fair value of these instruments is recorded as part of other comprehensive income (loss) and is amortized to interest expense over the life of the underlying debt. Upon issuance of the underlying fixed-rate notes in March 2015, we terminated forward-starting interest rate contracts in designated cash flow hedging instruments with an aggregate notional amount of $1.35 billion and paid $206.3 million in cash to the counterparties for settlement. The settlement amount represented the fair value of the forward-starting interest rate contracts at the time of termination and was recorded in other comprehensive loss. In connection with the note purchase and redemption discussed above, we terminated certain interest rate swaps designated as fair value hedges with an aggregate notional amount of $876.0 million . As a result of the termination, we received cash of $20.2 million , which represented the fair value of the interest rate swaps at the time of termination. The related fair value adjustment was recorded as an increase to the carrying value of the underlying notes and was included as a component of the debt extinguishment loss. The Effect of Risk-Management Instruments on the Consolidated Condensed Statement of Operations The following effects of risk-management instruments were recognized in other–net, (income) expense: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Fair value hedges: Effect from hedged fixed-rate debt $ 66.1 $ (7.7 ) $ 25.8 $ 86.0 Effect from interest rate contracts (66.1 ) 7.7 (25.8 ) (86.0 ) Cash flow hedges: Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss (1) — 20.2 — 87.6 Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 3.7 2.3 10.0 6.7 Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments (14.9 ) (8.3 ) 7.2 12.7 (1) Realized gains on the sale of the underlying equity securities recognized in other–net, (income) expense for the three and nine months ended September 30, 2014 were $56.8 million and $183.1 million , respectively. The effective portion of net (losses) gains on equity contracts in designated cash flow hedging relationships recorded in other comprehensive loss was $(11.8) million and $108.7 million for the three and nine months ended September 30, 2014 , respectively. There were no equity contracts in designated cash flow hedging relationships during the three and nine months ended September 30, 2015 . During the next 12 months, we expect to reclassify from accumulated other comprehensive loss to earnings $14.7 million of pretax net losses on cash flow hedges of the variability in expected future interest payments on our floating rate debt. During the nine months ended September 30, 2015 and 2014 , net losses related to ineffectiveness, as well as net losses related to the portion of our risk-management hedging instruments, fair value hedges, and cash flow hedges that were excluded from the assessment of effectiveness, were not material. Fair Value of Financial Instruments The following tables summarize certain fair value information at September 30, 2015 and December 31, 2014 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Description Carrying Amount Amortized Cost Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2015 Cash equivalents $ 1,537.8 $ 1,537.8 $ 1,381.9 $ 155.9 $ — $ 1,537.8 Short-term investments: U.S. government and agencies $ 301.5 $ 301.4 $ 301.5 $ — $ — $ 301.5 Corporate debt securities 770.9 770.8 — 770.9 — 770.9 Asset-backed securities 3.5 3.5 — 3.5 — 3.5 Other securities 4.5 4.5 — 4.5 — 4.5 Short-term investments $ 1,080.4 $ 1,080.2 Noncurrent investments: U.S. government and agencies $ 412.2 $ 411.6 $ 411.2 $ 1.0 $ — $ 412.2 Corporate debt securities 2,306.9 2,331.5 — 2,306.9 — 2,306.9 Mortgage-backed securities 161.7 161.6 — 161.7 — 161.7 Asset-backed securities 494.7 494.6 — 494.7 — 494.7 Other securities 4.6 4.6 — 4.6 — 4.6 Marketable equity securities 85.0 45.3 85.0 — — 85.0 Other investments (1) 636.9 636.9 Noncurrent investments $ 4,102.0 $ 4,086.1 December 31, 2014 Cash equivalents $ 2,443.5 $ 2,443.5 $ 2,415.5 $ 28.0 $ — $ 2,443.5 Short-term investments: U.S. government and agencies $ 185.5 $ 185.6 $ 156.5 $ 29.0 $ — $ 185.5 Corporate debt securities 767.4 766.7 — 767.4 — 767.4 Other securities 2.5 2.5 — 2.5 — 2.5 Short-term investments $ 955.4 $ 954.8 Noncurrent investments: U.S. government and agencies $ 756.7 $ 757.5 $ 747.5 $ 9.2 $ — $ 756.7 Corporate debt securities 2,462.7 2,468.9 — 2,462.7 — 2,462.7 Mortgage-backed securities 217.0 217.6 — 217.0 — 217.0 Asset-backed securities 477.8 478.0 — 477.8 — 477.8 Other securities 3.2 3.2 — 3.2 — 3.2 Marketable equity securities 204.8 44.0 204.8 — — 204.8 Other investments (1) 446.7 446.7 Noncurrent investments $ 4,568.9 $ 4,415.9 (1) Primarily includes investments accounted for under the cost method and equity method for which fair value disclosures are not applicable. Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term borrowings (1) September 30, 2015 $ — $ — $ — $ — $ — December 31, 2014 (2,680.6 ) — (2,680.6 ) — (2,680.6 ) Long-term debt, including current portion September 30, 2015 $ (8,078.9 ) $ — $ (8,191.5 ) $ — $ (8,191.5 ) December 31, 2014 (5,340.9 ) — (5,722.1 ) — (5,722.1 ) (1) Represents short-term commercial paper borrowings Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2015 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 107.4 $ — $ 107.4 $ — $ 107.4 Foreign exchange contracts not designated as hedging instruments: Other receivables 16.2 — 16.2 — 16.2 Other current liabilities (11.3 ) — (11.3 ) — (11.3 ) December 31, 2014 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 102.5 $ — $ 102.5 $ — $ 102.5 Other current liabilities (149.5 ) — (149.5 ) — (149.5 ) Other noncurrent liabilities (0.7 ) — (0.7 ) — (0.7 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.1 — 9.1 — 9.1 Other current liabilities (14.0 ) — (14.0 ) — (14.0 ) Risk-management instruments above are disclosed on a gross basis. There are various rights of setoff associated with certain of the risk-management instruments above that are subject to an enforceable master netting arrangement or similar agreements. Although various rights of setoff and master netting arrangements or similar agreements may exist with the individual counterparties to the risk-management instruments above, individually, these financial rights are not material. We determine fair values based on a market approach using quoted market values, significant other observable inputs for identical or comparable assets or liabilities, or discounted cash flow analyses. The fair value of equity method investments and other investments is not readily available. The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2015 : Maturities by Period Total Less Than 1 Year 2-5 Years 6-10 Years More Than 10 Years Fair value of debt securities $ 4,460.5 $ 1,080.4 $ 3,034.4 $ 165.3 $ 180.4 A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: September 30, 2015 December 31, 2014 Unrealized gross gains $ 54.8 $ 171.9 Unrealized gross losses 38.7 18.3 Fair value of securities in an unrealized gain position 2,012.6 1,778.8 Fair value of securities in an unrealized loss position 2,365.8 3,129.2 We periodically assess our investment securities for other-than-temporary impairment losses. Other-than-temporary impairment losses recorded during the three and nine months ended September 30, 2015 were $31.5 million and $41.3 million , respectively, and related primarily to our equity method and other investments. Other-than-temporary impairment losses recorded during the three and nine months ended September 30, 2014 were $3.6 million and $11.0 million , respectively. For fixed-income securities, the amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. For equity securities, factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, our intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, and general market conditions and industry specific factors. As of September 30, 2015 , the securities in an unrealized loss position include primarily fixed-rate debt securities of varying maturities. The value of fixed-income securities is sensitive to changes in the yield curve and other market conditions. Approximately 80 percent of the securities in a loss position are investment-grade debt securities. As of September 30, 2015 , we do not intend to sell, and it is not more likely than not that we will be required to sell the securities in a loss position before the market values recover or the underlying cash flows have been received, and there is no indication of default on interest or principal payments for any of our debt securities. Activity related to our investment portfolio, substantially all of which related to available-for-sale securities and other investments, was as follows: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Proceeds from sales $ 621.9 $ 2,491.2 $ 3,491.8 $ 9,680.4 Realized gross gains on sales 151.0 92.7 253.3 257.3 Realized gross losses on sales 1.5 1.1 3.9 16.2 Realized gains and losses on sales of investments are computed based upon specific identification of the initial cost adjusted for any other-than-temporary declines in fair value that were recorded in earnings.

Goodwill and Other Intangibles

Goodwill and Other Intangibles Goodwill and Other Intangibles	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	Note 7: Goodwill and Other Intangibles Goodwill by segment was as follows: September 30, 2015 December 31, 2014 Human pharmaceutical $ 1,359.2 $ 1,359.4 Animal health 2,695.7 398.7 Total goodwill $ 4,054.9 $ 1,758.1 The increase in goodwill for the animal health segment is due to the acquisition of Novartis AH (Note 3). The components of intangible assets other than goodwill were as follows: September 30, 2015 December 31, 2014 Description Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Finite-lived intangible assets: Marketed products $ 7,708.6 $ (3,357.6 ) $ 4,351.0 $ 5,684.3 $ (2,915.6 ) $ 2,768.7 Other 147.6 (57.4 ) 90.2 149.3 (45.2 ) 104.1 Total finite-lived intangible assets 7,856.2 (3,415.0 ) 4,441.2 5,833.6 (2,960.8 ) 2,872.8 Indefinite-lived intangible assets: In-process research and development 174.7 — 174.7 11.4 — 11.4 Other intangibles $ 8,030.9 $ (3,415.0 ) $ 4,615.9 $ 5,845.0 $ (2,960.8 ) $ 2,884.2 The increases in marketed products and acquired IPR&D assets in 2015 are primarily due to the acquisition of Novartis AH (Note 3). Amortization expense related to finite-lived intangible assets was as follows: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Amortization expense $ 154.1 $ 134.0 $ 461.7 $ 399.9 See Note 3 for further discussion of intangible assets acquired in recent business combinations.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2015
Equity, Class of Treasury Stock [Line Items]
Stockholders' Equity Note Disclosure [Text Block]	Note 8: Shareholders’ Equity During the nine months ended September 30, 2015 and 2014, we purchased $496.6 million and $500.0 million of shares, respectively, associated with our $5.00 billion share repurchase program announced in October 2013. As of September 30, 2015 , there were $3.20 billion of shares remaining in that program.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	Note 9: Income Taxes The U.S. examination of tax years 2010 - 2012 commenced during the fourth quarter of 2013 and is expected to be completed by the end of 2015. We currently estimate that it is reasonably possible there will be a reduction in gross uncertain tax positions of approximately $400 million by the end of 2015. It is also possible that up to $250 million of cash payments will be due upon resolution of the 2010 - 2012 tax years. We do not expect that resolution of the U.S. examination will result in a material change to our consolidated financial position. We anticipate that the U.S. examination of tax years 2013 - 2014 , and possibly 2015 , will begin in 2016.

Retirement Benefits

Retirement Benefits	9 Months Ended
	Sep. 30, 2015
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Retirement Benefits [Text Block]	Note 10: Retirement Benefits Net pension and retiree health benefit expense included the following components: Defined Benefit Pension Plans Three Months Ended Nine Months Ended 2015 2014 2015 2014 Components of net periodic benefit cost: Service cost $ 82.8 $ 65.4 $ 245.3 $ 195.7 Interest cost 117.1 118.3 351.4 355.5 Expected return on plan assets (195.7 ) (188.9 ) (579.7 ) (567.3 ) Amortization of prior service cost 2.5 0.9 7.6 2.7 Recognized actuarial loss 91.5 68.8 274.8 207.3 Net periodic benefit cost $ 98.2 $ 64.5 $ 299.4 $ 193.9 Retiree Health Benefit Plans Three Months Ended Nine Months Ended 2015 2014 2015 2014 Components of net periodic benefit income: Service cost $ 10.5 $ 10.3 $ 31.5 $ 33.2 Interest cost 15.3 20.9 46.0 64.7 Expected return on plan assets (37.1 ) (36.0 ) (111.3 ) (107.9 ) Amortization of prior service cost (21.6 ) (7.4 ) (64.8 ) (22.0 ) Recognized actuarial loss 9.4 5.0 28.3 15.1 Net periodic benefit income $ (23.5 ) $ (7.2 ) $ (70.3 ) $ (16.9 ) On a global basis, we have contributed approximately $40 million required to satisfy minimum funding requirements to our defined benefit pension and retiree health benefit plans in 2015. Additional discretionary funding in the aggregate was approximately $260 million during the nine months ended September 30, 2015 . During the remainder of 2015, we expect to make contributions to our defined benefit pension and retiree health benefit plans of approximately $10 million to satisfy minimum funding requirements. Additional discretionary funding for the remainder of the year is not expected to be material.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2015
Loss Contingency, Information about Litigation Matters [Abstract]
Contingencies [Text Block]	Note 11: Contingencies We are a party to various legal actions and government investigations. The most significant of these are described below. It is not possible to determine the outcome of these matters and we cannot reasonably estimate the maximum potential exposure or the range of possible loss in excess of amounts accrued for any of these matters; however, we believe that, except as noted below with respect to the Alimta ® patent litigation and administrative proceedings, the resolution of all such matters will not have a material adverse effect on our consolidated financial position or liquidity, but could possibly be material to our consolidated results of operations in any one accounting period. Alimta Patent Litigation and Administrative Proceedings A number of generic manufacturers are seeking approvals in various countries to market generic forms of Alimta prior to the expiration of our vitamin regimen patents, alleging that those patents are invalid, not infringed, or both. We believe our Alimta vitamin regimen patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the ultimate outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. An unfavorable outcome could have a material adverse impact on our future consolidated results of operations, liquidity, and financial position. We expect that a loss of exclusivity for Alimta would result in a rapid and severe decline in future revenues in the relevant market. U.S. Patent Litigation We are engaged in various U.S. patent litigation matters involving Alimta brought pursuant to procedures set out in the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act). More than ten Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of Alimta prior to the expiration of our vitamin regimen patent (expiring in 2021 plus pediatric exclusivity expiring in 2022) have been filed by a number of companies, including Teva Parenteral Medicines, Inc. (Teva) and APP Pharmaceuticals, LLC (APP). These companies have also alleged the patent is invalid. In October 2010, we filed a lawsuit in the U.S. District Court for the Southern District of Indiana against Teva, APP and two other defendants seeking rulings that the U.S. vitamin regimen patent is valid and infringed (the Teva/APP litigation). Teva and APP stipulated to infringement of our vitamin regimen patent, with the contingency that Teva and APP would be permitted to litigate the issue of infringement if the U.S. Supreme Court vacated an en banc decision of the U.S. Court of Appeals for the Federal Circuit that dealt with the issues of liability related to infringement ( Akamai v. Limelight Networks ). Thus, the sole issue before the district court was to determine the issue of patent validity. Trial occurred in August 2013. In March 2014, the court ruled that the asserted claims of the vitamin regimen patent are valid. In June 2014, the U.S. Supreme Court vacated the Akamai decision, and the U.S. District Court for the Southern District of Indiana held a hearing on the issue of infringement in May 2015. In September 2015, the U.S. District Court for the Southern District of Indiana ruled that the vitamin regimen patent would be infringed by the generic challengers' proposed products. Teva and APP filed a notice of appeal with respect to all of the district court’s substantive decisions. A decision from the U.S. Court of Appeals for the Federal Circuit is expected next year. Throughout the course of 2012 through 2015, we filed similar lawsuits against other ANDA defendants seeking a ruling that our patents are valid and infringed. The majority of these cases have been stayed pending the outcome of the Teva/APP litigation, and these parties have agreed to be bound by the outcome of the Teva/APP litigation. European Patent Litigation and Administrative Proceedings Generic manufacturers filed an opposition to the European Patent Office's (EPO) decision to grant us a vitamin regimen patent. The Opposition Division of the EPO upheld the patent and the generic manufacturers lodged an appeal. The EPO appeal hearing was scheduled for November 2015. In October 2015 the generic manufacturers withdrew the appeal, and the hearing was canceled. As a result, the original EPO decision upholding the patent will now be final. In addition, in the United Kingdom (U.K.), Actavis Group ehf and other Actavis companies (collectively, Actavis) filed litigation asking for a declaratory judgment that commercialization of certain salt forms of pemetrexed (the active ingredient in Alimta) would not infringe the vitamin regimen patents in the U.K., Italy, France, and Spain. In May 2014, the trial court ruled that the vitamin regimen patents for Alimta would not be infringed by commercialization of alternative salt forms of pemetrexed, after expiration of the compound patents in December 2015. We appealed, and in June 2015, the U.K. Court of Appeal reversed the trial court, ruling that the Alimta vitamin regimen patent in the U.K. would be indirectly infringed by commercialization of Actavis' products as proposed prior to the patent's expiration in June 2021. The Court of Appeal also held there was no difference between the law in the U.K. and that in France, Italy, and Spain as it relates to indirect infringement, and so reversed the trial court's decision granting declarations of noninfringement over the Alimta vitamin regimen patents in those countries. We and Actavis have asked for permission to appeal different aspects of the Court of Appeals’ judgment to the U.K. Supreme Court. The U.K. Supreme Court has not yet decided if it will consider the case. Actavis has asked the trial court for a declaratory judgment that commercialization of a different proposed product would not infringe the patent in the U.K., Italy, France, and Spain. Trial on this matter was originally scheduled for November 2015, but has been postponed and is expected to be rescheduled for early 2016. We commenced separate infringement proceedings against certain Actavis companies in Germany. Following a trial, in April 2014, the German trial court ruled in our favor. The defendants appealed, and after a hearing in March 2015, the appellate court overturned the trial court and ruled that our vitamin regimen patent in Germany would not be infringed by a dipotassium salt form of pemetrexed. We have asked for permission to appeal this ruling to the German Supreme Court. Japanese Administrative Proceedings Three companies have filed demands for invalidation of our vitamin regimen patents with the Japanese Patent Office (JPO). A hearing was held on one of the demands in February 2015. In October 2015, the JPO issued a notice of closure in the invalidation trial relating to the parent case, one of two currently pending decisions relating to the February 2015 hearing. We expect to receive a written decision upholding our patent in the parent case within a few weeks. We also expect a ruling in the other pending decision soon. This is the first of several decisions relating to the vitamin regimen patents before the JPO. Effient Patent Litigation and Administrative Proceedings We, along with Daiichi Sankyo, Daiichi Sankyo, Inc., and Ube Industries (Ube) are engaged in various U.S. patent litigation matters involving Effient brought pursuant to procedures set out in the Hatch-Waxman Act. More than ten different companies have submitted ANDAs seeking approval to market generic versions of Effient prior to the expiration of Daiichi Sankyo’s and Ube’s patents (expiring in 2022) covering methods of using Effient with aspirin, and alleging the patents are invalid. One of these ANDAs also alleges that the compound patent for Effient (expiring in 2017) is invalid. Beginning in March 2014, we filed lawsuits in the U.S. District Court for the Southern District of Indiana against these companies, seeking a ruling that the patents are valid and infringed. The majority of these cases have been consolidated. The remainder have been stayed, and the parties have agreed to be bound by the outcome of the consolidated litigation. In 2015, several generic pharmaceutical companies filed petitions with the U.S. Patent and Trademark Office, requesting inter partes review of the method patents. In September 2015, the U.S. Patent and Trademark Office granted the generic pharmaceutical companies' request and scheduled review in mid-2016. We believe the Effient patents are valid and enforceable against these generic manufacturers. However, it is not possible to determine the outcome of the proceedings, and accordingly, we can provide no assurance that we will prevail. We expect a loss of exclusivity for Effient would result in a rapid and severe decline in future revenues for the product in the relevant market. Actos ® Product Liability Litigation We are named along with Takeda Chemical Industries, Ltd., and Takeda affiliates (collectively, Takeda) as a defendant in approximately 6,500 product liability cases in the U.S. related to the diabetes medication Actos, which we co-promoted with Takeda in the U.S. from 1999 until 2006. In general, plaintiffs in these actions allege that Actos caused or contributed to their bladder cancer. Almost all of the active cases have been consolidated in federal multi-district litigation in the Western District of Louisiana or are pending in a coordinated state court proceeding in California or a coordinated state court proceeding in Illinois. We believe these lawsuits are without merit, and we and Takeda are prepared to defend against them vigorously. In April 2014, a jury in the Western District of Louisiana found in favor of the plaintiffs in the case of Allen, et al. v. Takeda Pharmaceuticals, et al., no. 6:12-md-00064. In September 2014, judgment was entered awarding $1.3 million in compensatory damages to plaintiffs (allocated 75 percent to Takeda and 25 percent to us) and punitive damages of $6.00 billion against Takeda and $3.00 billion against us. In October 2014, the judge reduced the amount of punitive damages awarded to approximately $28 million against Takeda and approximately $9 million against us. We continue to believe the evidence did not support plaintiffs’ claims and strongly disagree with the verdict. We and Takeda appealed this judgment and plaintiffs filed a cross-appeal objecting to the reduction in punitive damages; however, in light of the proposed resolution described below, both appeals have been dismissed without prejudice, subject to reinstatement by any party within six months of the dismissal. Our agreement with Takeda calls for Takeda to defend and indemnify us against our losses and expenses with respect to the U.S. litigation arising out of the manufacture, use, or sale of Actos and other related expenses in accordance with the terms of the agreement. After the jury reached its verdict in Allen , Takeda notified us that it was reserving its right to challenge its obligations to defend and indemnify us with respect to the Allen case. We believe we are entitled to full indemnification of our losses and expenses in Allen and all other U.S. cases ; however, there can be no guarantee we will ultimately be successful in obtaining full indemnification. In April 2015, Takeda announced they will pay approximately $2.4 billion to resolve the vast majority of the U.S. product liability lawsuits involving Actos, including Allen , and the other cases involving us. This resolution will become effective if at least 95 percent of current litigants opt into the Actos product liability resolution program, and will release us and Takeda of all remaining liability for these cases. In September 2015, Takeda announced that more than 96 percent of eligible claimants have opted into the resolution program that was announced in April 2015. Takeda is now evaluating the submissions to determine whether they satisfy various criteria specified under terms of the resolution program. Takeda expects the resolution program to become effective upon completion of that review. We are also named along with Takeda as a defendant in three purported product liability class actions in Canada related to Actos, including one in Ontario ( Casseres et al. v. Takeda Pharmaceutical North America, Inc., et al .), one in Quebec ( Whyte et al. v. Eli Lilly et al. ), and one in Alberta ( Epp v. Takeda Canada et al. ). We promoted Actos in Canada until 2009. These claims are not part of the U.S. resolution program. We believe these claims are without merit and are prepared to defend against them vigorously. Byetta Product Liability Litigation We are named as a defendant in approximately 500 Byetta product liability lawsuits involving approximately 1,050 plaintiffs. Approximately 110 of these lawsuits, covering about 640 plaintiffs, are filed in California state court and coordinated in a Los Angeles Superior Court. Approximately 380 lawsuits, covering about 385 plaintiffs, are filed in federal court, the majority of which are coordinated in a multi-district litigation in the Southern District of California. The remaining approximately five lawsuits, representing about 20 plaintiffs, are in various state courts. Approximately 435 of the lawsuits, involving approximately 675 plaintiffs, contain allegations that Byetta caused or contributed to the plaintiffs' cancer (primarily pancreatic cancer or thyroid cancer). We are aware of approximately 220 additional claimants who have not yet filed suit. The majority of these additional claims allege damages for pancreatitis. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously. Prozac ® Product Liability Litigation We are named as a defendant in approximately 10 U.S. lawsuits primarily related to allegations that the antidepressant Prozac caused or contributed to birth defects in the children of women who ingested the drug during pregnancy. We are aware of approximately 535 additional claims related to birth defects, which have not yet been filed. We believe these lawsuits and claims are without merit and are prepared to defend against them vigorously. Brazil–Employee Litigation Our subsidiary in Brazil, Eli Lilly do Brasil (Lilly Brasil), is named in a lawsuit brought by the Labor Attorney for 15th Region in the Labor Court of Paulinia, State of Sao Paulo, Brazil, alleging possible harm to employees and former employees caused by exposure to heavy metals at a former Lilly manufacturing facility in Cosmopolis, Brazil, operated by the company between 1977 and 2003. The plaintiffs allege that some employees at the facility were exposed to benzene and heavy metals; however, Lilly Brasil maintains that these alleged contaminants were never used in the facility. In May 2014, the labor court judge ruled against Lilly Brasil. The judge's ruling orders Lilly Brasil to undertake several actions of unspecified financial impact, including paying lifetime medical insurance for the employees and contractors who worked at the Cosmopolis facility more than six months during the affected years and their children born during and after this period. While we cannot currently estimate the range of reasonably possible financial losses that could arise in the event we do not ultimately prevail in the litigation, the judge has estimated the total financial impact of the ruling to be approximately 1.0 billion Brazilian real (approximately $250 million as of September 30, 2015 ) plus interest. We strongly disagree with the decision and filed an appeal in May 2014. We are also named in approximately 30 lawsuits filed in the same court by individual former employees making similar claims. We believe these lawsuits are without merit and are prepared to defend against them vigorously. Product Liability Insurance Because of the nature of pharmaceutical products, it is possible that we could become subject to large numbers of product liability and related claims in the future. Due to a very restrictive market for product liability insurance, we are self-insured for product liability losses for all our currently marketed products.

Other Comprehensive Income (Los

Other Comprehensive Income (Loss) Other Comprehensive Income (Loss) (Notes)	9 Months Ended
	Sep. 30, 2015
Comprehensive Income (Loss) Note [Text Block]	Note 12: Other Comprehensive Income (Loss) The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended September 30, 2015 and 2014 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2015 $ (1,037.6 ) $ 121.0 $ (3,263.3 ) $ (223.3 ) $ (4,403.2 ) Other comprehensive income (loss) before reclassifications (226.7 ) (16.2 ) 16.2 — (226.7 ) Net amount reclassified from accumulated other comprehensive loss — (94.3 ) 54.8 2.4 (37.1 ) Net other comprehensive income (loss) (226.7 ) (110.5 ) 71.0 2.4 (263.8 ) Balance at September 30, 2015 $ (1,264.3 ) $ 10.5 $ (3,192.3 ) $ (220.9 ) $ (4,667.0 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2014 $ 467.9 $ 124.7 $ (2,403.3 ) $ (124.6 ) $ (1,935.3 ) Other comprehensive income (loss) before reclassifications (635.4 ) 17.3 36.5 (34.5 ) (616.1 ) Net amount reclassified from accumulated other comprehensive loss — (59.5 ) 44.7 14.6 (0.2 ) Net other comprehensive income (loss) (635.4 ) (42.2 ) 81.2 (19.9 ) (616.3 ) Balance at September 30, 2014 $ (167.5 ) $ 82.5 $ (2,322.1 ) $ (144.5 ) $ (2,551.6 ) The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2015 and 2014 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2015 $ (498.4 ) $ 99.7 $ (3,402.0 ) $ (191.1 ) $ (3,991.8 ) Other comprehensive income (loss) before reclassifications (765.9 ) 42.9 46.8 (36.9 ) (713.1 ) Net amount reclassified from accumulated other comprehensive loss — (132.1 ) 162.9 7.1 37.9 Net other comprehensive income (loss) (765.9 ) (89.2 ) 209.7 (29.8 ) (675.2 ) Balance at September 30, 2015 $ (1,264.3 ) $ 10.5 $ (3,192.3 ) $ (220.9 ) $ (4,667.0 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2014 $ 463.0 $ 205.2 $ (2,489.1 ) $ (181.8 ) $ (2,002.7 ) Other comprehensive income (loss) before reclassifications (630.5 ) 34.0 30.0 (23.8 ) (590.3 ) Net amount reclassified from accumulated other comprehensive loss — (156.7 ) 137.0 61.1 41.4 Net other comprehensive income (loss) (630.5 ) (122.7 ) 167.0 37.3 (548.9 ) Balance at September 30, 2014 $ (167.5 ) $ 82.5 $ (2,322.1 ) $ (144.5 ) $ (2,551.6 ) The tax effects allocated to each component of other comprehensive income (loss) for the three and nine months ended September 30 , were as follows: Three Months Ended Nine Months Ended Tax (benefit) expense 2015 2014 2015 2014 Foreign currency translation losses $ (5.9 ) $ — $ (17.7 ) $ — Unrealized net losses on securities (59.6 ) (22.8 ) (48.2 ) (66.3 ) Defined benefit pension and retiree health benefit plans 31.1 30.8 93.9 70.8 Effective portion of cash flow hedges 1.3 (10.7 ) (15.9 ) 19.9 Provision for income taxes allocated to other comprehensive income (loss) $ (33.1 ) $ (2.7 ) $ 12.1 $ 24.4 Except for the tax effects of foreign currency translation gains (losses) related to our euro-denominated notes (see Note 6), income taxes were not provided for foreign currency translation. Generally, the assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows; therefore, resulting translation adjustments are made in shareholders' equity rather than in income. Reclassifications Out of Accumulated Other Comprehensive Loss Details about Accumulated Other Comprehensive Loss Components Three Months Ended Nine Months Ended Affected Line Item in the Consolidated Condensed Statements of Operations 2015 2014 2015 2014 Amortization of retirement benefit items: Prior service benefits, net $ (19.1 ) $ (6.5 ) $ (57.2 ) $ (19.3 ) (1) Actuarial losses 100.9 73.8 303.1 222.4 (1) Total before tax 81.8 67.3 245.9 203.1 Tax benefit (27.0 ) (22.6 ) (83.0 ) (66.1 ) Income taxes Net of tax 54.8 44.7 162.9 137.0 Unrealized gains/losses on available-for-sale securities: Realized gains, net before tax (149.5 ) (91.6 ) (213.9 ) (241.1 ) Other–net, (income) expense Impairment losses 4.5 — 10.7 — Other–net, (income) expense Total before tax (145.0 ) (91.6 ) (203.2 ) (241.1 ) Tax expense 50.7 32.1 71.1 84.4 Income taxes Net of tax (94.3 ) (59.5 ) (132.1 ) (156.7 ) Other, net of tax 2.4 14.6 7.1 61.1 Other–net, (income) expense Total reclassifications for the period (net of tax) $ (37.1 ) $ (0.2 ) $ 37.9 $ 41.4 (1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (see Note 10).

Other-Net, (Income) Expense

Other-Net, (Income) Expense	9 Months Ended
	Sep. 30, 2015
Nonoperating Income (Expense) [Abstract]
Other - Net, Expense (Income) [Text Block]	Note 13: Other–Net, (Income) Expense Other–net, (income) expense consisted of the following: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Interest expense $ 39.3 $ 38.1 $ 117.0 $ 111.4 Interest income (21.2 ) (28.8 ) (63.2 ) (96.8 ) Debt extinguishment loss (Note 6) — — 166.7 — Other income (104.6 ) (102.8 ) (276.4 ) (217.9 ) Other–net, (income) expense $ (86.5 ) $ (93.5 ) $ (55.9 ) $ (203.3 ) Other income consists primarily of net gains on investments.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 14: Segment Information We operate in two business segments—human pharmaceutical and animal health products. Our business segments are distinguished by the ultimate end user of the product—humans or animals. Performance is evaluated based on profit or loss from operations before income taxes. The animal health segment amounts for the three and nine months ended September 30, 2015 include the results of operations from Novartis AH which was acquired on January 1, 2015. See Note 3 for additional information regarding the Novartis AH acquisition. Three Months Ended Nine Months Ended 2015 2014 2015 2014 Segment revenue—to unaffiliated customers: Human pharmaceutical: Endocrinology: Humalog ® $ 705.0 $ 706.1 $ 2,043.3 $ 2,056.1 Forteo ® 348.9 332.2 970.4 941.2 Humulin ® 316.7 335.9 948.8 1,004.5 Trajenta 92.7 78.9 255.0 246.1 Evista ® 58.0 89.5 184.5 347.8 Trulicity ® 73.7 — 136.2 — Other Endocrinology 191.4 165.7 512.4 491.3 Total Endocrinology 1,786.4 1,708.3 5,050.6 5,087.0 Neuroscience: Cymbalta ® 242.9 368.0 804.0 1,247.5 Zyprexa ® 237.9 257.4 711.2 784.2 Strattera ® 196.9 191.9 562.4 543.7 Other Neuroscience 46.8 52.6 136.0 152.5 Total Neuroscience 724.5 869.9 2,213.6 2,727.9 Oncology: Alimta 628.5 723.4 1,865.8 2,067.0 Erbitux 85.9 92.9 308.8 277.3 Cyramza ® 111.2 28.4 266.4 42.0 Other Oncology 35.7 37.7 101.8 118.8 Total Oncology 861.3 882.4 2,542.8 2,505.1 Cardiovascular: Cialis ® 566.1 568.4 1,672.3 1,668.6 Effient 132.1 131.5 382.7 384.4 Other Cardiovascular 61.7 57.3 183.3 182.3 Total Cardiovascular 759.9 757.2 2,238.3 2,235.3 Other pharmaceuticals 48.8 73.1 168.5 225.7 Total human pharmaceutical 4,180.9 4,290.9 12,213.8 12,781.0 Animal health 778.8 584.7 2,369.3 1,713.3 Revenue $ 4,959.7 $ 4,875.6 $ 14,583.1 $ 14,494.3 Three Months Ended Nine Months Ended 2015 2014 2015 2014 Segment profits: Human pharmaceutical $ 1,124.1 $ 760.0 $ 3,224.0 $ 2,350.8 Animal health 139.8 145.8 443.1 417.6 Total segment profits $ 1,263.9 $ 905.8 $ 3,667.1 $ 2,768.4 Reconciliation of total segment profits to consolidated income before taxes: Segment profits $ 1,263.9 $ 905.8 $ 3,667.1 $ 2,768.4 Other profits (losses): Acquired in-process research and development (Note 3) — (95.0 ) (336.0 ) (95.0 ) Amortization of intangible assets (1) (152.5 ) — (457.2 ) — Asset impairment, restructuring, and other special charges (Note 5) (42.4 ) (36.3 ) (222.8 ) (67.7 ) Debt repurchase charges, net (2) (Note 6) — — (152.7 ) — Inventory fair value adjustment related to Novartis AH (Note 3) (21.2 ) — (153.0 ) — Incremental U.S. Branded Prescription Drug Fee due to issuance of final tax regulations — (119.0 ) — (119.0 ) Consolidated income before taxes $ 1,047.8 $ 655.5 $ 2,345.4 $ 2,486.7 (1) In 2015, the measurement of segment profitability was changed to exclude the amortization of intangible assets. If we were to adjust the three months ended September 30, 2014 to conform with the 2015 presentation and exclude amortization of intangible assets, the human pharmaceutical and animal health segment profits would be increased by $118.9 million and $15.7 million , respectively, and $352.4 million and $43.1 million for the nine months ended September 30, 2014 , respectively. (2) We recognized pretax net charges of $152.7 million for the nine months ended September 30, 2015 , attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes. For internal management reporting presented to the chief operating decision maker, certain costs are fully allocated to our human pharmaceutical segment and therefore are not reflected in the animal health segment's profit. Such items include costs associated with treasury-related financing, global administrative services, certain acquisition-related transaction costs, and certain manufacturing costs.

Financial Instruments (Policies

Financial Instruments (Policies)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Description of Derivative Risk Management Policy	Accounting Policy for Risk-Management Instruments Our derivative activities are initiated within the guidelines of documented corporate risk-management policies and offset losses and gains on the assets, liabilities, and transactions being hedged. Management reviews the correlation and effectiveness of our derivatives on a quarterly basis. For derivative contracts that are designated and qualify as fair value hedges, the derivative instrument is marked to market with gains and losses recognized currently in income to offset the respective losses and gains recognized on the underlying exposure. For derivative contracts that are designated and qualify as cash flow hedges, the effective portion of gains and losses on these contracts is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same period the hedged transaction affects earnings. Hedge ineffectiveness is immediately recognized in earnings. Derivative contracts that are not designated as hedging instruments are recorded at fair value with the gain or loss recognized in current earnings during the period of change. We may enter into foreign currency forward or option contracts to reduce the effect of fluctuating currency exchange rates (principally the euro, the British pound, and the Japanese yen). Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures. Forward and option contracts are principally used to manage exposures arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. These contracts are recorded at fair value with the gain or loss recognized in other–net, (income) expense. We may enter into foreign currency forward and option contracts and currency swaps as fair value hedges of firm commitments. Forward contracts generally have maturities not exceeding 12 months.

Implementation of New Financi22

Implementation of New Financial Accounting Pronouncements Implementation of New Accounting Pronouncements (Tables)	9 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Standard Description Effective Date Effect on the financial statements or other significant matters Accounting Standards Update 2014-09, Revenue from Contracts with Customers This standard will replace existing revenue recognition standards and will require entities to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. In August 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2015-14, Revenue from Contracts with Customers , which deferred the effective date of the new revenue recognition standard by one year (to January 1, 2018 for us), but permits entities to adopt the new standard on the original effective date if they choose. We are evaluating our anticipated date of adoption. There are areas within the standard that are currently under review and reconsideration by the FASB, which could lead to updates to the standard. As the outcomes of this review and reconsideration could lead to significant changes to the standard, we are still in the process of determining our approach to the adoption of the standard, as well as the anticipated impact to our consolidated financial statements.

Acquisitions Acquistions (Table

Acquisitions Acquistions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Acquisition [Line Items]
Schedule of Research and Development Assets Acquired Other than Through Business Combination [Table Text Block]	The following table summarizes our product and other acquisitions which are discussed in detail below: Counterparty Compound(s) or Therapy Acquisition Month Phase of Development (1) Acquired IPR&D Expense Innovent Biologics, Inc. (Innovent) Monoclonal antibody targeting protein CD-20 Immuno-oncology molecules cMet monoclonal antibody March 2015 Pre-clinical (2) $ 56.0 Hanmi Pharmaceutical Co., Ltd. (Hanmi) BTK Inhibitor - HM71224 April 2015 Phase I 50.0 BioNTech AG (BioNTech) Cancer immunotherapies May 2015 Pre-clinical 30.0 Immunocore Limited (Immunocore) T cell-based cancer therapies July 2014 Pre-clinical 45.0 AstraZeneca UK Limited (AstraZeneca) Oral beta-secretase cleaving enzyme inhibitor - AZD3293 September 2014 Phase I 50.0
Novartis Animal Health [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma financial information presents the combined consolidated results of our operations with Novartis AH as if the portion of Novartis AH that we retained after the sale to Virbac had been acquired as of January 1, 2014. We have adjusted the historical consolidated financial information to give effect to pro forma events that are directly attributable to the acquisition. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations would have been had we completed the acquisition at the beginning of 2014. In addition, the unaudited pro forma financial information does not attempt to project the future results of operations of our combined company. Unaudited Pro Forma Consolidated Results Three Months Ended Nine Months Ended 2015 2014 2015 2014 Revenue $ 4,959.7 $ 5,151.0 $ 14,583.1 $ 15,297.1 Net income 815.0 452.8 2,039.6 1,723.7 Diluted earnings per share 0.77 0.42 1.91 1.60
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at January 1, 2015 Inventories $ 380.2 Acquired in-process research and development 295.0 Marketed products (1) 1,940.0 Property and equipment 218.9 Assets held for sale (primarily the U.S. Sentinel rights) 422.7 Accrued retirement benefits (167.6 ) Deferred income taxes (57.4 ) Other assets and liabilities - net (38.9 ) Total identifiable net assets 2,992.9 Goodwill (2) 2,290.2 Total consideration transferred - net of cash acquired $ 5,283.1
Lohmann Animal Health [Member]
Business Acquisition [Line Items]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date: Estimated Fair Value at April 30, 2014 Marketed products $ 275.4 Other intangible assets 23.9 Property and equipment 81.9 Deferred income taxes (92.7 ) Other assets and liabilities - net 51.1 Total identifiable net assets 339.6 Goodwill (1) 251.6 Total consideration transferred - net of cash acquired $ 591.2

Collaborations (Tables)

Collaborations (Tables)	9 Months Ended
	Sep. 30, 2015
Diabetes Collaboration [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	Product Status Milestones (Earned) Expensed (1) Milestones (Deferred) Capitalized (2) Product Family U.S. Europe Japan Year Amount Year Amount Trajenta (3) Launched 2011 Launched 2011 Launched 2011 2015 $ — 2015 $ — 2014 — 2014 — 2013 — 2013 — Cumulative (6) 446.4 Jardiance (4) Launched 2014 Launched 2014 Launched 2015 2015 — 2015 — 2014 — 2014 299.5 2013 97.2 2013 — Cumulative (6) 299.5 Basaglar Tentatively Approved (5) Launched 2015 Launched 2015 2015 — 2015 — 2014 — 2014 (62.5 ) 2013 (50.0 ) 2013 — Cumulative (6) (62.5 )
Trajenta (BI) [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our revenue recognized with respect to the Trajenta family of products: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Collaboration and other revenue $ 92.7 $ 78.9 $ 255.0 $ 246.1
Erbitux [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our revenue recognized with respect to Erbitux: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Net product revenues $ (2.3 ) $ 8.8 $ 22.6 $ 34.5 Collaboration and other revenue 88.2 84.1 286.2 242.8 Revenue $ 85.9 $ 92.9 $ 308.8 $ 277.3
Effient [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	Three Months Ended Nine Months Ended 2015 2014 2015 2014 Revenue $ 132.1 $ 131.5 $ 382.7 $ 384.4
Selling, General and Administrative Expenses [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our aggregate amount of marketing, selling, and administrative expense associated with our commission and profit-sharing obligations for the collaborations and other arrangements described above: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Marketing, selling, and administrative $ 53.6 $ 53.5 $ 156.5 $ 155.4
Collaborative Arrangement [Member]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	The following table summarizes our collaboration and other revenue recognized: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Collaboration and other revenue $ 215.2 $ 204.0 $ 644.7 $ 593.9

Asset Impairment, Restructuri25

Asset Impairment, Restructuring, and Other Special Charges Asset Impairment, Restructuring, and Other Special Charges (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the components of the recognized charges included in asset impairment, restructuring, and other special charges by segment: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Severance: Human pharmaceutical $ 9.6 $ 17.1 $ 26.5 $ 36.5 Animal health 2.5 — 38.8 — Total severance 12.1 17.1 65.3 36.5 Asset impairment and other special charges: Human pharmaceutical 0.9 2.7 18.0 14.7 Animal health 29.4 16.5 139.5 16.5 Asset impairment and other special charges 30.3 19.2 157.5 31.2 Asset impairment, restructuring, and other special charges $ 42.4 $ 36.3 $ 222.8 $ 67.7

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]	The following effects of risk-management instruments were recognized in other–net, (income) expense: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Fair value hedges: Effect from hedged fixed-rate debt $ 66.1 $ (7.7 ) $ 25.8 $ 86.0 Effect from interest rate contracts (66.1 ) 7.7 (25.8 ) (86.0 ) Cash flow hedges: Effective portion of losses on equity contracts reclassified from accumulated other comprehensive loss (1) — 20.2 — 87.6 Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss 3.7 2.3 10.0 6.7 Net (gains) losses on foreign currency exchange contracts not designated as hedging instruments (14.9 ) (8.3 ) 7.2 12.7 (1) Realized gains on the sale of the underlying equity securities recognized in other–net, (income) expense for the three and nine months ended September 30, 2014 were $56.8 million and $183.1 million , respectively.
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	The following tables summarize certain fair value information at September 30, 2015 and December 31, 2014 for assets and liabilities measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Description Carrying Amount Amortized Cost Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2015 Cash equivalents $ 1,537.8 $ 1,537.8 $ 1,381.9 $ 155.9 $ — $ 1,537.8 Short-term investments: U.S. government and agencies $ 301.5 $ 301.4 $ 301.5 $ — $ — $ 301.5 Corporate debt securities 770.9 770.8 — 770.9 — 770.9 Asset-backed securities 3.5 3.5 — 3.5 — 3.5 Other securities 4.5 4.5 — 4.5 — 4.5 Short-term investments $ 1,080.4 $ 1,080.2 Noncurrent investments: U.S. government and agencies $ 412.2 $ 411.6 $ 411.2 $ 1.0 $ — $ 412.2 Corporate debt securities 2,306.9 2,331.5 — 2,306.9 — 2,306.9 Mortgage-backed securities 161.7 161.6 — 161.7 — 161.7 Asset-backed securities 494.7 494.6 — 494.7 — 494.7 Other securities 4.6 4.6 — 4.6 — 4.6 Marketable equity securities 85.0 45.3 85.0 — — 85.0 Other investments (1) 636.9 636.9 Noncurrent investments $ 4,102.0 $ 4,086.1 December 31, 2014 Cash equivalents $ 2,443.5 $ 2,443.5 $ 2,415.5 $ 28.0 $ — $ 2,443.5 Short-term investments: U.S. government and agencies $ 185.5 $ 185.6 $ 156.5 $ 29.0 $ — $ 185.5 Corporate debt securities 767.4 766.7 — 767.4 — 767.4 Other securities 2.5 2.5 — 2.5 — 2.5 Short-term investments $ 955.4 $ 954.8 Noncurrent investments: U.S. government and agencies $ 756.7 $ 757.5 $ 747.5 $ 9.2 $ — $ 756.7 Corporate debt securities 2,462.7 2,468.9 — 2,462.7 — 2,462.7 Mortgage-backed securities 217.0 217.6 — 217.0 — 217.0 Asset-backed securities 477.8 478.0 — 477.8 — 477.8 Other securities 3.2 3.2 — 3.2 — 3.2 Marketable equity securities 204.8 44.0 204.8 — — 204.8 Other investments (1) 446.7 446.7 Noncurrent investments $ 4,568.9 $ 4,415.9
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value Short-term borrowings (1) September 30, 2015 $ — $ — $ — $ — $ — December 31, 2014 (2,680.6 ) — (2,680.6 ) — (2,680.6 ) Long-term debt, including current portion September 30, 2015 $ (8,078.9 ) $ — $ (8,191.5 ) $ — $ (8,191.5 ) December 31, 2014 (5,340.9 ) — (5,722.1 ) — (5,722.1 )
Fair Value, by Balance Sheet Grouping [Table Text Block]	Fair Value Measurements Using Description Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value September 30, 2015 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 107.4 $ — $ 107.4 $ — $ 107.4 Foreign exchange contracts not designated as hedging instruments: Other receivables 16.2 — 16.2 — 16.2 Other current liabilities (11.3 ) — (11.3 ) — (11.3 ) December 31, 2014 Risk-management instruments Interest rate contracts designated as hedging instruments: Sundry $ 102.5 $ — $ 102.5 $ — $ 102.5 Other current liabilities (149.5 ) — (149.5 ) — (149.5 ) Other noncurrent liabilities (0.7 ) — (0.7 ) — (0.7 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 9.1 — 9.1 — 9.1 Other current liabilities (14.0 ) — (14.0 ) — (14.0 )
Available-for-sale Securities [Table Text Block]	A summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss follows: September 30, 2015 December 31, 2014 Unrealized gross gains $ 54.8 $ 171.9 Unrealized gross losses 38.7 18.3 Fair value of securities in an unrealized gain position 2,012.6 1,778.8 Fair value of securities in an unrealized loss position 2,365.8 3,129.2 The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of September 30, 2015 : Maturities by Period Total Less Than 1 Year 2-5 Years 6-10 Years More Than 10 Years Fair value of debt securities $ 4,460.5 $ 1,080.4 $ 3,034.4 $ 165.3 $ 180.4
Gain (Loss) on Investments [Table Text Block]	Activity related to our investment portfolio, substantially all of which related to available-for-sale securities and other investments, was as follows: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Proceeds from sales $ 621.9 $ 2,491.2 $ 3,491.8 $ 9,680.4 Realized gross gains on sales 151.0 92.7 253.3 257.3 Realized gross losses on sales 1.5 1.1 3.9 16.2

Goodwill and Other Intangible27

Goodwill and Other Intangibles Goodwill and Other Intangibles (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill [Table Text Block]	Goodwill by segment was as follows: September 30, 2015 December 31, 2014 Human pharmaceutical $ 1,359.2 $ 1,359.4 Animal health 2,695.7 398.7 Total goodwill $ 4,054.9 $ 1,758.1
Schedule of Intangible Assets and Goodwill [Table Text Block]	The components of intangible assets other than goodwill were as follows: September 30, 2015 December 31, 2014 Description Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Carrying Amount— Gross Accumulated Amortization Carrying Amount— Net Finite-lived intangible assets: Marketed products $ 7,708.6 $ (3,357.6 ) $ 4,351.0 $ 5,684.3 $ (2,915.6 ) $ 2,768.7 Other 147.6 (57.4 ) 90.2 149.3 (45.2 ) 104.1 Total finite-lived intangible assets 7,856.2 (3,415.0 ) 4,441.2 5,833.6 (2,960.8 ) 2,872.8 Indefinite-lived intangible assets: In-process research and development 174.7 — 174.7 11.4 — 11.4 Other intangibles $ 8,030.9 $ (3,415.0 ) $ 4,615.9 $ 5,845.0 $ (2,960.8 ) $ 2,884.2
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to finite-lived intangible assets was as follows: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Amortization expense $ 154.1 $ 134.0 $ 461.7 $ 399.9

Retirement Benefits (Tables)

Retirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2015
Pension Plans, Defined Benefit [Member]
Schedule of Net Benefit Costs [Table Text Block]	Net pension and retiree health benefit expense included the following components: Defined Benefit Pension Plans Three Months Ended Nine Months Ended 2015 2014 2015 2014 Components of net periodic benefit cost: Service cost $ 82.8 $ 65.4 $ 245.3 $ 195.7 Interest cost 117.1 118.3 351.4 355.5 Expected return on plan assets (195.7 ) (188.9 ) (579.7 ) (567.3 ) Amortization of prior service cost 2.5 0.9 7.6 2.7 Recognized actuarial loss 91.5 68.8 274.8 207.3 Net periodic benefit cost $ 98.2 $ 64.5 $ 299.4 $ 193.9
Other Postretirement Benefit Plans, Defined Benefit [Member]
Schedule of Net Benefit Costs [Table Text Block]	Retiree Health Benefit Plans Three Months Ended Nine Months Ended 2015 2014 2015 2014 Components of net periodic benefit income: Service cost $ 10.5 $ 10.3 $ 31.5 $ 33.2 Interest cost 15.3 20.9 46.0 64.7 Expected return on plan assets (37.1 ) (36.0 ) (111.3 ) (107.9 ) Amortization of prior service cost (21.6 ) (7.4 ) (64.8 ) (22.0 ) Recognized actuarial loss 9.4 5.0 28.3 15.1 Net periodic benefit income $ (23.5 ) $ (7.2 ) $ (70.3 ) $ (16.9 )

Other Comprehensive Income (L29

Other Comprehensive Income (Loss) Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	(Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2014 $ 463.0 $ 205.2 $ (2,489.1 ) $ (181.8 ) $ (2,002.7 ) Other comprehensive income (loss) before reclassifications (630.5 ) 34.0 30.0 (23.8 ) (590.3 ) Net amount reclassified from accumulated other comprehensive loss — (156.7 ) 137.0 61.1 41.4 Net other comprehensive income (loss) (630.5 ) (122.7 ) 167.0 37.3 (548.9 ) Balance at September 30, 2014 $ (167.5 ) $ 82.5 $ (2,322.1 ) $ (144.5 ) $ (2,551.6 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2015 $ (1,037.6 ) $ 121.0 $ (3,263.3 ) $ (223.3 ) $ (4,403.2 ) Other comprehensive income (loss) before reclassifications (226.7 ) (16.2 ) 16.2 — (226.7 ) Net amount reclassified from accumulated other comprehensive loss — (94.3 ) 54.8 2.4 (37.1 ) Net other comprehensive income (loss) (226.7 ) (110.5 ) 71.0 2.4 (263.8 ) Balance at September 30, 2015 $ (1,264.3 ) $ 10.5 $ (3,192.3 ) $ (220.9 ) $ (4,667.0 ) (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at July 1, 2014 $ 467.9 $ 124.7 $ (2,403.3 ) $ (124.6 ) $ (1,935.3 ) Other comprehensive income (loss) before reclassifications (635.4 ) 17.3 36.5 (34.5 ) (616.1 ) Net amount reclassified from accumulated other comprehensive loss — (59.5 ) 44.7 14.6 (0.2 ) Net other comprehensive income (loss) (635.4 ) (42.2 ) 81.2 (19.9 ) (616.3 ) Balance at September 30, 2014 $ (167.5 ) $ 82.5 $ (2,322.1 ) $ (144.5 ) $ (2,551.6 ) The following tables summarize the activity related to each component of other comprehensive income (loss) during the nine months ended September 30, 2015 and 2014 : (Amounts presented net of taxes) Foreign Currency Translation Gains (Losses) Unrealized Net Gains (Losses) on Securities Defined Benefit Pension and Retiree Health Benefit Plans Effective Portion of Cash Flow Hedges Accumulated Other Comprehensive Loss Balance at January 1, 2015 $ (498.4 ) $ 99.7 $ (3,402.0 ) $ (191.1 ) $ (3,991.8 ) Other comprehensive income (loss) before reclassifications (765.9 ) 42.9 46.8 (36.9 ) (713.1 ) Net amount reclassified from accumulated other comprehensive loss — (132.1 ) 162.9 7.1 37.9 Net other comprehensive income (loss) (765.9 ) (89.2 ) 209.7 (29.8 ) (675.2 ) Balance at September 30, 2015 $ (1,264.3 ) $ 10.5 $ (3,192.3 ) $ (220.9 ) $ (4,667.0 ) The tax effects allocated to each component of other comprehensive income (loss) for the three and nine months ended September 30 , were as follows: Three Months Ended Nine Months Ended Tax (benefit) expense 2015 2014 2015 2014 Foreign currency translation losses $ (5.9 ) $ — $ (17.7 ) $ — Unrealized net losses on securities (59.6 ) (22.8 ) (48.2 ) (66.3 ) Defined benefit pension and retiree health benefit plans 31.1 30.8 93.9 70.8 Effective portion of cash flow hedges 1.3 (10.7 ) (15.9 ) 19.9 Provision for income taxes allocated to other comprehensive income (loss) $ (33.1 ) $ (2.7 ) $ 12.1 $ 24.4
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	Reclassifications Out of Accumulated Other Comprehensive Loss Details about Accumulated Other Comprehensive Loss Components Three Months Ended Nine Months Ended Affected Line Item in the Consolidated Condensed Statements of Operations 2015 2014 2015 2014 Amortization of retirement benefit items: Prior service benefits, net $ (19.1 ) $ (6.5 ) $ (57.2 ) $ (19.3 ) (1) Actuarial losses 100.9 73.8 303.1 222.4 (1) Total before tax 81.8 67.3 245.9 203.1 Tax benefit (27.0 ) (22.6 ) (83.0 ) (66.1 ) Income taxes Net of tax 54.8 44.7 162.9 137.0 Unrealized gains/losses on available-for-sale securities: Realized gains, net before tax (149.5 ) (91.6 ) (213.9 ) (241.1 ) Other–net, (income) expense Impairment losses 4.5 — 10.7 — Other–net, (income) expense Total before tax (145.0 ) (91.6 ) (203.2 ) (241.1 ) Tax expense 50.7 32.1 71.1 84.4 Income taxes Net of tax (94.3 ) (59.5 ) (132.1 ) (156.7 ) Other, net of tax 2.4 14.6 7.1 61.1 Other–net, (income) expense Total reclassifications for the period (net of tax) $ (37.1 ) $ (0.2 ) $ 37.9 $ 41.4

Other - Net, (Income) Expense

Other - Net, (Income) Expense (Tables)	9 Months Ended
	Sep. 30, 2015
Nonoperating Income (Expense) [Abstract]
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Other–net, (income) expense consisted of the following: Three Months Ended Nine Months Ended 2015 2014 2015 2014 Interest expense $ 39.3 $ 38.1 $ 117.0 $ 111.4 Interest income (21.2 ) (28.8 ) (63.2 ) (96.8 ) Debt extinguishment loss (Note 6) — — 166.7 — Other income (104.6 ) (102.8 ) (276.4 ) (217.9 ) Other–net, (income) expense $ (86.5 ) $ (93.5 ) $ (55.9 ) $ (203.3 )

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting Information [Line Items]
Segment Information [Text Block]	Three Months Ended Nine Months Ended 2015 2014 2015 2014 Segment revenue—to unaffiliated customers: Human pharmaceutical: Endocrinology: Humalog ® $ 705.0 $ 706.1 $ 2,043.3 $ 2,056.1 Forteo ® 348.9 332.2 970.4 941.2 Humulin ® 316.7 335.9 948.8 1,004.5 Trajenta 92.7 78.9 255.0 246.1 Evista ® 58.0 89.5 184.5 347.8 Trulicity ® 73.7 — 136.2 — Other Endocrinology 191.4 165.7 512.4 491.3 Total Endocrinology 1,786.4 1,708.3 5,050.6 5,087.0 Neuroscience: Cymbalta ® 242.9 368.0 804.0 1,247.5 Zyprexa ® 237.9 257.4 711.2 784.2 Strattera ® 196.9 191.9 562.4 543.7 Other Neuroscience 46.8 52.6 136.0 152.5 Total Neuroscience 724.5 869.9 2,213.6 2,727.9 Oncology: Alimta 628.5 723.4 1,865.8 2,067.0 Erbitux 85.9 92.9 308.8 277.3 Cyramza ® 111.2 28.4 266.4 42.0 Other Oncology 35.7 37.7 101.8 118.8 Total Oncology 861.3 882.4 2,542.8 2,505.1 Cardiovascular: Cialis ® 566.1 568.4 1,672.3 1,668.6 Effient 132.1 131.5 382.7 384.4 Other Cardiovascular 61.7 57.3 183.3 182.3 Total Cardiovascular 759.9 757.2 2,238.3 2,235.3 Other pharmaceuticals 48.8 73.1 168.5 225.7 Total human pharmaceutical 4,180.9 4,290.9 12,213.8 12,781.0 Animal health 778.8 584.7 2,369.3 1,713.3 Revenue $ 4,959.7 $ 4,875.6 $ 14,583.1 $ 14,494.3 Three Months Ended Nine Months Ended 2015 2014 2015 2014 Segment profits: Human pharmaceutical $ 1,124.1 $ 760.0 $ 3,224.0 $ 2,350.8 Animal health 139.8 145.8 443.1 417.6 Total segment profits $ 1,263.9 $ 905.8 $ 3,667.1 $ 2,768.4 Reconciliation of total segment profits to consolidated income before taxes: Segment profits $ 1,263.9 $ 905.8 $ 3,667.1 $ 2,768.4 Other profits (losses): Acquired in-process research and development (Note 3) — (95.0 ) (336.0 ) (95.0 ) Amortization of intangible assets (1) (152.5 ) — (457.2 ) — Asset impairment, restructuring, and other special charges (Note 5) (42.4 ) (36.3 ) (222.8 ) (67.7 ) Debt repurchase charges, net (2) (Note 6) — — (152.7 ) — Inventory fair value adjustment related to Novartis AH (Note 3) (21.2 ) — (153.0 ) — Incremental U.S. Branded Prescription Drug Fee due to issuance of final tax regulations — (119.0 ) — (119.0 ) Consolidated income before taxes $ 1,047.8 $ 655.5 $ 2,345.4 $ 2,486.7

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ / shares in Units, $ in Millions		Apr. 30, 2014	Oct. 31, 2015	Jan. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jan. 01, 2015	Dec. 31, 2014
Document Period End Date									Sep. 30, 2015
Amortization of Intangible Assets					$ 154.1			$ 134	$ 461.7	$ 399.9
Cost of sales					1,236.9			1,267	3,648	3,679.4
Interest Expense					39.3			38.1	117	111.4
Restricted cash					0				0			$ 5,405.6
Payments to Acquire Businesses, Net of Cash Acquired									5,287.8	551.4
Goodwill					4,054.9				4,054.9			$ 1,758.1
Acquired in-process research and development					0			95	336	95
Purchased in-process research and development									386	45
Novartis Animal Health [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory											$ 380.2
Business Combination, Consideration Transferred				$ 5,280
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	[1]										1,940
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets											295
Business Combination, Consideration Transferred											5,283.1
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				19 years
Business Acquisition, Goodwill, Expected Tax Deductible Amount											950
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual					255.5				760
Business Acquisition, Pro Forma Revenue					4,959.7			5,151	14,583.1	15,297.1
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment											218.9
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets held for sale											422.7
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other											(167.6)
Goodwill	[2]										2,290.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent											(57.4)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities											(38.9)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net											$ 2,992.9
Business Acquisition, Pro Forma Net Income (Loss)					$ 815			$ 452.8	$ 2,039.6	$ 1,723.7
Business Acquisition, Pro Forma Earnings Per Share, Diluted					$ 0.77			$ 0.42	$ 1.91	$ 1.60
Lohmann Animal Health [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets		$ 51.1
Business Combination, Consideration Transferred		591.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		275.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles, Other Intangible Assets		23.9
Business Combination, Consideration Transferred		591.2
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		81.9
Payments to Acquire Businesses, Net of Cash Acquired		551.4
Goodwill		251.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent		(92.7)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		339.6
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt		$ 39.8
Immunocore Limited [Member]
Acquired in-process research and development								$ 45
AstraZeneca [Member]
Acquired in-process research and development								50
Innovent Biologics, Inc. [Member]
Acquired in-process research and development							$ 56
Hanmi Pharmaceutical Co., Ltd. [Member]
Acquired in-process research and development						$ 50
BioNTech AG [Member]
Acquired in-process research and development						$ 30
Tanezumab [Member]
Acquired in-process research and development							$ 200
Subsequent Event [Member]
Purchased in-process research and development			$ 150
Discontinued Operations, Held-for-sale [Member] | United States [Member] | U.S. Sentinel Product Line [Member]
Proceeds from Divestiture of Businesses				$ 410
Amortization of Fair Value Adjusted Intangible Assets [Member] | Novartis Animal Health [Member]
Amortization of Intangible Assets								26		$ 78
Fair Value Adjustment to Inventory [Member] | Novartis Animal Health [Member]
Cost of sales					$ (21)			21	$ (153)	153
Acquisition-related Costs [Member] | Novartis Animal Health [Member]
Interest Expense								31	82
Corporate, Non-Segment [Member]
Amortization of Intangible Assets	[3]				152.5			0	457.2	0
Acquired in-process research and development					0			95	336	95
Corporate, Non-Segment [Member] | Fair Value Adjustment to Inventory [Member]
Cost of sales					$ 21.2			$ 0	$ 153	$ 0
[1]	(1) These intangible assets, which will be amortized to cost of sales on a straight-line basis over their estimated useful lives, are expected to have a weighted average useful life of 19 years.
[2]	(2) The goodwill recognized from this acquisition is attributable primarily to expected synergies that we believe will result from combining the operations of Novartis AH with our legacy Animal Health operations, future unidentified projects and products, and the assembled workforce of Novartis AH. Approximately $950 million of the goodwill associated with this acquisition is estimated to be deductible for tax purposes.
[3]	(1) In 2015, the measurement of segment profitability was changed to exclude the amortization of intangible assets. If we were to adjust the three months ended September 30, 2014 to conform with the 2015 presentation and exclude amortization of intangible assets, the human pharmaceutical and animal health segment profits would be increased by $118.9 million and $15.7 million, respectively, and $352.4 million and $43.1 million for the nine months ended September 30, 2014, respectively.

Collaborations (Details)

Collaborations (Details) - USD ($) $ in Millions		1 Months Ended					3 Months Ended				6 Months Ended	9 Months Ended		10 Months Ended	12 Months Ended
		Oct. 31, 2013	Aug. 31, 2012	Nov. 30, 2011	Dec. 31, 2009	Jun. 30, 2001	Dec. 31, 2015	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Jun. 30, 2011	Sep. 30, 2015	Sep. 30, 2014	Oct. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Oct. 01, 2015
Collaboration and other revenue								$ 215.2		$ 204		$ 644.7	$ 593.9
Revenue								4,959.7		4,875.6		14,583.1	14,494.3
Research and development								1,143.4		1,243.2		3,352.2	3,547.9
Nonoperating Income (Expense)								86.5		93.5		55.9	203.3
Marketing, selling, and administrative								1,575.7		1,672.1		4,734.6	4,820.9
Goodwill								4,054.9				4,054.9			$ 1,758.1
Acquired in-process research and development								0		95		336	95
Amortization of Intangible Assets								154.1		134		461.7	399.9
Erbitux [Member]
Collaboration and other revenue								88.2		84.1		286.2	242.8
Revenue								85.9		92.9		308.8	277.3
Sales Revenue, Goods, Net								(2.3)		8.8		22.6	34.5
Effient [Member]
Revenue								132.1		131.5		382.7	384.4
Trajenta (BI) [Member]
Collaboration and other revenue										78.9			246.1
Tanezumab [Member]
Acquired in-process research and development									$ 200
Sales [Member] | Outside the United States [Member] | Exenatide [Member]
Collaborative Arrangement, Rights and Obligations Percent														100.00%
Revenue Share [Member] | Amylin [Member]
Collaborative Arrangement, Rights and Obligations, Terms			$ 1,260
Profit and Development and Marketing Share [Member] | Effient [Member]
Collaborative Arrangement, Rights and Obligations Percent						50.00%
Research and Development Exp [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent					30.00%
Milestone Payments [Member] | Solanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms											$ (70)
Milestone Payments, Development and Regulatory, Capitalized [Member] | Lly Compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[1],[2]											0			62.5	$ 0
Milestone Payments, Development and Regulatory, Capitalized [Member] | Trajenta (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[1],[3]											0			0	0
Milestone Payments, Development and Regulatory, Capitalized [Member] | Jardiance (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[1],[4]											0			(299.5)	0
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Lly Compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[1],[2],[5]											62.5
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Trajenta (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[1],[3],[5]											(446.4)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative [Member] | Jardiance (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[1],[4],[5]											(299.5)
Milestone Payments, Development and Regulatory, Expensed [Member] | Lly Compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[6]											0			0	50
Milestone Payments, Development and Regulatory, Expensed [Member] | Trajenta (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[3],[6]											0			0	0
Milestone Payments, Development and Regulatory, Expensed [Member] | Jardiance (BI) [Member]
Collaborative Arrangement, Rights and Obligations, Terms	[4],[6]											0			$ 0	$ (97.2)
Milestone Payments, Sales-based [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations, Terms					$ (150)
Milestone Payments, Sales-based [Member] | Tanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms		$ (1,230)
Milestone Payments, Development and Regulatory [Member] | Lly Compounds [Member]
Collaborative Arrangement, Rights and Obligations, Terms												(187.5)
Milestone Payments, Development and Regulatory [Member] | Amylin [Member]
Collaborative Arrangement, Rights and Obligations, Terms				$ 150
Milestone Payments, Development and Regulatory [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations, Terms					$ (415)
Milestone Payments, Development and Regulatory [Member] | Tanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms		$ (350)
Royalty Agreement Terms [Member] | Solanezumab [Member]
Collaborative Arrangement, Rights and Obligations, Terms of Arrangement, Period											10 years
Royalty Agreement Terms [Member] | Baricitinib [Member]
Collaborative Arrangement, Rights and Obligations Percent					20.00%
Upfront Payment [Member] | Amylin [Member]
Collaborative Arrangement, Rights and Obligations, Terms				$ 250
Collaborative Arrangement [Member]
Marketing, selling, and administrative								53.6		53.5		156.5	155.4
Subsequent Event [Member] | Sales [Member] | Erbitux [Member]
Collaborative Arrangement, Rights and Obligations Percent							38.00%
Cardiovascular [Member]
Revenue								759.9		757.2		2,238.3	2,235.3
Cardiovascular [Member] | Effient [Member]
Revenue								$ 132.1		$ 131.5			$ 384.4
Erbitux Acquisition [Member]
Business Acquisition, Pro Forma Revenue												$ 14,832
Erbitux Acquisition [Member] | Subsequent Event [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles																	$ 550
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory																	50
Goodwill																	50
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability																	$ 650
[1]	(2) In connection with the regulatory approvals of Basaglar in Europe and Japan, milestone payments received were recorded as deferred revenue and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In the future, we will be eligible to receive up to $187.5 million in success-based regulatory milestones on Basaglar. In connection with the regulatory approvals of Trajenta and Jardiance, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales.
[2]	(5) Basaglar received tentative approval in the U.S. in August 2014. The U.S. Food and Drug Administration (FDA) has determined that Basaglar meets all regulatory requirements for approval, but final approval was subject to a delay of up to 30 months as a result of patent infringement litigation filed by Sanofi-Aventis U.S. LLC (Sanofi), which markets Lantus® (insulin glargine). In September 2015, we entered into a settlement agreement to resolve the patent litigation with Sanofi. As part of the agreement and pending FDA approval, Basaglar can be launched in the U.S. beginning on December 15, 2016.
[3]	(3) Jentadueto® is included in the Trajenta family of product results.
[4]	(4) Glyxambi® and Synjardy® are included in the Jardiance family of product results.
[5]	(6) The cumulative amount represents the total amounts as of the end of the reporting period that have been (deferred) or capitalized since the start of this collaboration.
[6]	(1) Milestones earned for Basaglar as a result of regulatory submissions were recorded as income in other-net, (income) expense. Milestones expensed for Jardiance as a result of regulatory submissions were recorded as research and development expenses.

Asset Impairment, Restructuri34

Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Restructuring Cost and Reserve [Line Items]
Document Period End Date			Sep. 30, 2015
Document Fiscal Year Focus			2,015
Severance Costs	$ 12.1	$ 17.1	$ 65.3	$ 36.5
Asset Impairment Charges	30.3	19.2	157.5	31.2
Asset impairment, restructuring, and other special charges	42.4	36.3	222.8	67.7
Human Pharmaceutical Products [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	9.6	17.1	26.5	36.5
Asset Impairment Charges	0.9	2.7	18	14.7
Animal Health [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	2.5	0	38.8	0
Asset Impairment Charges	$ 29.4	$ 16.5	$ 139.5	$ 16.5

Financial Instruments (Details)

Financial Instruments (Details) € in Millions, ¥ in Millions, £ in Millions, $ in Millions		1 Months Ended		3 Months Ended			9 Months Ended
		Jun. 30, 2015USD ($)	Feb. 28, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015EUR (€)	Sep. 30, 2015GBP (£)	Sep. 30, 2015USD ($)	Sep. 30, 2015JPY (¥)	Jun. 30, 2015EUR (€)	Jun. 02, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax											$ 54.8					$ 171.9
Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax											38.7					18.3
Translation Adjustment Functional to Reporting Currency, Increase (Decrease), Gross of Tax				$ 16.8		$ 0	$ (50.6)	$ 0
Available-for-sale Securities, Gross Realized Gains				151		92.7	253.3	257.3
Repayments of Long-term Debt					$ 1,950		1,950.6	1,034.3
Available-for-sale Securities, Debt Securities											$ 4,460.5
Proceeds from issuance of long-term debt							4,454.6	992.9
Extinguishment of Debt, Amount					1,650
Debt extinguishment loss				$ 0		0	$ 166.7	0
Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Other, Percentage of Nonperforming Assets							80.00%
Maximum Remaining Maturity of Foreign Currency Derivatives				30 days
Description of Derivative Activity Volume Percent									40.00%	40.00%	40.00%	40.00%
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net											$ 14.7
Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value											3,034.4
Available-for-sale Securities, Continuous Unrealized Gain Position, Fair Value											2,012.6					1,778.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value											2,365.8					3,129.2
Other than Temporary Impairment Losses, Investments				$ 31.5		3.6	$ 41.3	11
Proceeds from Sale and Maturity of Available-for-sale Securities				621.9		2,491.2	3,491.8	9,680.4
Available-for-sale Securities, Gross Realized Losses				1.5		1.1	3.9	16.2
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value											1,080.4
Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value											165.3
Available-for-sale Securities, Debt Maturities, after Ten Years, Fair Value											180.4
Net proceeds (payments) for terminations of interest rate swaps							(186.1)	252.5
Maturity Date, 2018 [Member]
Long-term Debt															$ (600)
Debt Instrument, Interest Rate, Stated Percentage															1.25%
Maturity Date, 2025 [Member]
Long-term Debt															$ (800)
Debt Instrument, Interest Rate, Stated Percentage															2.75%
Maturity Date, 2045 [Member]
Long-term Debt															$ (800)
Debt Instrument, Interest Rate, Stated Percentage															3.70%
Maturity Date, 2022 [Member] [Member]
Long-term Debt | €													€ (600)
Debt Instrument, Interest Rate, Stated Percentage													1.00%
Maturity Date, 2026 [Member]
Long-term Debt | €													€ (750)
Debt Instrument, Interest Rate, Stated Percentage													1.63%
Maturity Date, 2030 [Member]
Long-term Debt | €													€ (750)
Debt Instrument, Interest Rate, Stated Percentage													2.13%
Euro-Denominated Debt Issuance [Member]
Long-term Debt											(2,320)
Proceeds from issuance of long-term debt					2,270
Equity Contract [Member]
Available-for-sale Securities, Gross Realized Gains						56.8		183.1
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion	[1]			0		20.2	0	87.6
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net				0		(11.8)	0	108.7
Hedged Fixed-Rate Debt [Member]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge				66.1		(7.7)	25.8	86
Interest Rate Contract [Member]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments				(66.1)		7.7	(25.8)	(86)
Derivative Instruments, Loss Reclassified from Accumulated OCI into Income, Effective Portion				3.7		2.3	10	6.7
Available-for-sale Securities, Noncurrent [Abstract]
Derivative Liability, Notional Amount			$ 1,350
Derivative Asset, Notional Amount														$ 876
Net proceeds (payments) for terminations of interest rate swaps		$ 20.2	$ (206.3)
Foreign Exchange Contract [Member]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments				$ (14.9)		$ (8.3)	$ 7.2	$ 12.7
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Short-term Debt	[2]										0					(2,680.6)
Cash and Cash Equivalents, Fair Value Disclosure											1,537.8					2,443.5
Long-term Debt											(8,078.9)					(5,340.9)
Extinguishment of Debt, Amount					$ 1,780
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total											1,080.4					955.4
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total											4,102					4,568.9
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Assets, Noncurrent											107.4					102.5
Derivative Liabilities, Current																(149.5)
Derivative Liabilities, Noncurrent																(0.7)
Carrying (Reported) Amount, Fair Value Disclosure [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Assets, Current											16.2					9.1
Derivative Liabilities, Current											(11.3)					(14)
Available-for-Sale Securities, Amortized Cost [Member]
Cash and Cash Equivalents, Fair Value Disclosure											1,537.8					2,443.5
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Current, Total											1,080.2					954.8
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Noncurrent, Total											4,086.1					4,415.9
Fair Value, Inputs, Level 1 [Member]
Short-term Debt	[2]										0					0
Cash and Cash Equivalents, Fair Value Disclosure											1,381.9					2,415.5
Long-term Debt											0					0
Fair Value, Inputs, Level 1 [Member] | Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Assets, Noncurrent											0					0
Derivative Liabilities, Current																0
Derivative Liabilities, Noncurrent																0
Fair Value, Inputs, Level 1 [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Assets, Current											0					0
Derivative Liabilities, Current											0					0
Fair Value, Inputs, Level 2 [Member]
Short-term Debt	[2]										0					(2,680.6)
Cash and Cash Equivalents, Fair Value Disclosure											155.9					28
Long-term Debt											(8,191.5)					(5,722.1)
Fair Value, Inputs, Level 2 [Member] | Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Assets, Noncurrent											107.4					102.5
Derivative Liabilities, Current																(149.5)
Derivative Liabilities, Noncurrent																(0.7)
Fair Value, Inputs, Level 2 [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Assets, Current											16.2					9.1
Derivative Liabilities, Current											(11.3)					(14)
Fair Value, Inputs, Level 3 [Member]
Short-term Debt	[2]										0					0
Cash and Cash Equivalents, Fair Value Disclosure											0					0
Long-term Debt											0					0
Fair Value, Inputs, Level 3 [Member] | Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Assets, Noncurrent											0					0
Derivative Liabilities, Current																0
Derivative Liabilities, Noncurrent																0
Fair Value, Inputs, Level 3 [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Assets, Current											0					0
Derivative Liabilities, Current											0					0
Estimate of Fair Value, Fair Value Disclosure [Member]
Short-term Debt	[2]										0					(2,680.6)
Cash and Cash Equivalents, Fair Value Disclosure											1,537.8					2,443.5
Long-term Debt											(8,191.5)					(5,722.1)
Estimate of Fair Value, Fair Value Disclosure [Member] | Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative Assets, Noncurrent											107.4					102.5
Derivative Liabilities, Current																(149.5)
Derivative Liabilities, Noncurrent																(0.7)
Estimate of Fair Value, Fair Value Disclosure [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Assets, Current											16.2					9.1
Derivative Liabilities, Current											(11.3)					(14)
Corporate Debt Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											770.9					767.4
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											2,306.9					2,462.7
Corporate Debt Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											770.8					766.7
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											2,331.5					2,468.9
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0					0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											770.9					767.4
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											2,306.9					2,462.7
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0					0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Corporate Debt Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											770.9					767.4
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											2,306.9					2,462.7
US Government Agencies Debt Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											301.5					185.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											412.2					756.7
US Government Agencies Debt Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											301.4					185.6
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											411.6					757.5
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											301.5					156.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											411.2					747.5
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0					29
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											1					9.2
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0					0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
US Government Agencies Debt Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											301.5					185.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											412.2					756.7
Other Debt Obligations [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											4.5					2.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											4.6					3.2
Other Debt Obligations [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											4.5					2.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											4.6					3.2
Other Debt Obligations [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0					0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Other Debt Obligations [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											4.5					2.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											4.6					3.2
Other Debt Obligations [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0					0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Other Debt Obligations [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											4.5					2.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											4.6					3.2
Collateralized Mortgage Backed Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											161.7					217
Collateralized Mortgage Backed Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											161.6					217.6
Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											161.7					217
Collateralized Mortgage Backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Collateralized Mortgage Backed Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											161.7					217
Asset-backed Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											3.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											494.7					477.8
Asset-backed Securities [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											3.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											494.6					478
Asset-backed Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Asset-backed Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											3.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											494.7					477.8
Asset-backed Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											0
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											0					0
Asset-backed Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Current [Abstract]
Available-for-sale Securities, Debt Securities, Current											3.5
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Debt Securities, Noncurrent											494.7					477.8
Equity Securities, US [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent											85					204.8
Equity Securities, US [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent											45.3					44
Equity Securities, US [Member] | Fair Value, Inputs, Level 1 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent											85					204.8
Equity Securities, US [Member] | Fair Value, Inputs, Level 2 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent											0					0
Equity Securities, US [Member] | Fair Value, Inputs, Level 3 [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent											0					0
Equity Securities, US [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Available-for-sale Securities, Equity Securities, Noncurrent											85					204.8
Equity Method and Other Investments [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Other Long-term Investments	[3]										636.9					446.7
Equity Method and Other Investments [Member] | Available-for-Sale Securities, Amortized Cost [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Other Long-term Investments	[3]										636.9					$ 446.7
Buy British pound Sell euro [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Derivative Liability, Notional Amount | £										£ 79.2
Derivative Asset, Notional Amount | €									€ 107.9
Buy US dollar Sell euro [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Derivative Liability, Notional Amount											1,080
Derivative Asset, Notional Amount | €									956.5
Buy euro Sell US dollar [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Derivative Liability, Notional Amount | €									€ 1,060
Derivative Asset, Notional Amount											1,190
Buy US dollar Sell Japanese Yen [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Derivative Liability, Notional Amount											501.3
Derivative Asset, Notional Amount | ¥												¥ 60,150
Buy US dollar Sell British pound [Member]
Available-for-sale Securities, Noncurrent [Abstract]
Derivative Liability, Notional Amount											$ 289.2
Derivative Asset, Notional Amount | £										£ 187.7
[1]	(1) Realized gains on the sale of the underlying equity securities recognized in other–net, (income) expense for the three and nine months ended September 30, 2014 were $56.8 million and $183.1 million, respectively.
[2]	(1) Represents short-term commercial paper borrowings
[3]	(1) Primarily includes investments accounted for under the cost method and equity method for which fair value disclosures are not applicable.

Goodwill and Other Intangible36

Goodwill and Other Intangibles Goodwill and Other Intangibles (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 154.1	$ 134	$ 461.7	$ 399.9
Finite-Lived Intangible Assets, Gross	7,856.2		7,856.2		$ 5,833.6
Goodwill	4,054.9		4,054.9		1,758.1
Intangible Assets, Gross (Excluding Goodwill)	8,030.9		8,030.9		5,845
Finite-Lived Intangible Assets, Accumulated Amortization	(3,415)		(3,415)		(2,960.8)
Finite-Lived Intangible Assets, Net	4,441.2		4,441.2		2,872.8
Other intangibles, net	4,615.9		4,615.9		2,884.2
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	174.7		174.7		11.4
Finite-Lived Intangible Assets, Accumulated Amortization	0		0		0
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	7,708.6		7,708.6		5,684.3
Finite-Lived Intangible Assets, Accumulated Amortization	(3,357.6)		(3,357.6)		(2,915.6)
Finite-Lived Intangible Assets, Net	4,351		4,351		2,768.7
Other Intangible Assets [Member]
Indefinite-lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	147.6		147.6		149.3
Finite-Lived Intangible Assets, Accumulated Amortization	(57.4)		(57.4)		(45.2)
Finite-Lived Intangible Assets, Net	90.2		90.2		104.1
Animal Health [Member]
Indefinite-lived Intangible Assets [Line Items]
Goodwill	2,695.7		2,695.7		398.7
Human Pharmaceutical Products [Member]
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 1,359.2		$ 1,359.2		$ 1,359.4

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Oct. 31, 2013
Stockholders' Equity Note [Abstract]
Treasury Stock, Value, Acquired, Cost Method	$ 496.6	$ 500
Stock Repurchase Program, Authorized Amount			$ 5,000
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 3,200

Income Taxes Income Taxes (Deta

Income Taxes Income Taxes (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Examination [Line Items]
Income Tax Examination, Year under Examination	2,015	2,014	2,013	2,012	2,011	2,010
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 400
Income Tax Examination, Estimate of Cash Payment for Taxes from Settlement with Taxing Authority	$ 250

Retirement Benefits (Details)

Retirement Benefits (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Pension Contributions			$ 40
Defined Benefit Plan, Estimated Future Employer Contributions in Current Fiscal Year			10
Pension And Other Postretirement Benefit Contributions, Estimated Future Discretionary Contributions			260
Pension Plans, Defined Benefit [Member]
Defined Benefit Plan, Service Cost	$ 82.8	$ 65.4	245.3	$ 195.7
Defined Benefit Plan, Interest Cost	117.1	118.3	351.4	355.5
Defined Benefit Plan, Expected Return on Plan Assets	(195.7)	(188.9)	(579.7)	(567.3)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	2.5	0.9	7.6	2.7
Defined Benefit Plan, Actuarial Gain (Loss)	91.5	68.8	274.8	207.3
Defined Benefit Plan, Net Periodic Benefit Cost, Total	98.2	64.5	299.4	193.9
Other Postretirement Benefit Plans, Defined Benefit [Member]
Defined Benefit Plan, Service Cost	10.5	10.3	31.5	33.2
Defined Benefit Plan, Interest Cost	15.3	20.9	46	64.7
Defined Benefit Plan, Expected Return on Plan Assets	(37.1)	(36)	(111.3)	(107.9)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(21.6)	(7.4)	(64.8)	(22)
Defined Benefit Plan, Actuarial Gain (Loss)	9.4	5	28.3	15.1
Defined Benefit Plan, Net Periodic Benefit Cost, Total	$ (23.5)	$ (7.2)	$ (70.3)	$ (16.9)

Contingencies (Details)

Contingencies (Details) $ in Millions, BRL in Billions	1 Months Ended			3 Months Ended	9 Months Ended
	Sep. 30, 2015	Apr. 30, 2015USD ($)	Oct. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2015BRL
Compensatory Damages [Member] | Actos [Member]
Loss Contingency, Damages Awarded, Value				$ 1.3
Product Liability Litigation [Member] | Actos [Member]
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Target Opt In, Percent		95.00%
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Actual Opt In, Percent	96.00%
Multi District Litigation MDL [Member] | Byetta [Member]
Loss Contingency, Number of Lawsuits					380	380
Loss Contingency, Number of Plaintiffs					385	385
Product Liability Litigation [Member] | Byetta [Member]
Loss Contingency, Number of Lawsuits					500	500
Loss Contingency, Number of Plaintiffs					1,050	1,050
Loss Contingency, Number of Claimants					220	220
Product Liability Litigation [Member] | Prozac [Member]
Loss Contingency, Number of Lawsuits					10	10
Loss Contingency, Number of Claimants					535	535
Product Liability Litigation [Member] | Actos [Member]
Loss Contingency, Number of Cases					6,500	6,500
Product Liability Litigation [Member] | Damages from Product, Cancer [Member] | Byetta [Member]
Loss Contingency, Number of Lawsuits					435	435
Loss Contingency, Number of Plaintiffs					675	675
Product Liability Litigation [Member] | CANADA | Actos [Member]
Loss Contingency, Number of Cases					3	3
Product Liability Litigation [Member] | ONTARIO | Actos [Member]
Loss Contingency, Number of Cases					1	1
Product Liability Litigation [Member] | QUEBEC | Actos [Member]
Loss Contingency, Number of Cases					1	1
Product Liability Litigation [Member] | ALBERTA | Actos [Member]
Loss Contingency, Number of Cases					1	1
Product Liability Litigation [Member] | CALIFORNIA | Byetta [Member]
Loss Contingency, Number of Lawsuits					110	110
Loss Contingency, Number of Plaintiffs					640	640
Product Liability Litigation [Member] | Other states [Member] | Byetta [Member]
Loss Contingency, Number of Lawsuits					5	5
Loss Contingency, Number of Plaintiffs					20	20
Lilly Portion [Member] | Compensatory Damages [Member] | Actos [Member]
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Percent Share				25.00%
Lilly Portion [Member] | Punitive Damages [Member] | Actos [Member]
Loss Contingency, Damages Awarded, Value			$ 9	$ 3,000
Takeda Portion [Member] | Compensatory Damages [Member] | Actos [Member]
Loss Contingency, Parties Jointly and Severally Liable in Litigation, Percent Share				75.00%
Takeda Portion [Member] | Punitive Damages [Member] | Actos [Member]
Loss Contingency, Damages Awarded, Value			$ 28	$ 6,000
Takeda Portion [Member] | Product Liability Litigation [Member] | Actos [Member]
Litigation Settlement, Amount		$ 2,400
Employee Litigation [Member] | Brazil [Member]
Loss Contingency, Number of Lawsuits					30	30
Loss Contingency, Damages Awarded, Value					$ 250	BRL 1

Other Comprehensive Income (L41

Other Comprehensive Income (Loss) Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax		$ (5.9)	$ 0	$ (17.7)	$ 0
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Prior Service Cost Arising During Period, before Tax	[1]	(19.1)	(6.5)	(57.2)	(19.3)
Accumulated other comprehensive loss		(4,667)	(2,551.6)	(4,667)	(2,551.6)	$ (4,403.2)	$ (3,991.8)	$ (1,935.3)	$ (2,002.7)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		(226.7)	(616.1)	(713.1)	(590.3)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax		(37.1)	(0.2)	37.9	41.4
Other comprehensive loss, net of tax		(263.8)	(616.3)	(675.2)	(548.9)
Other Comprehensive Income (Loss), Reclassification, Pension and Other Postretirement Benefit Plans, Net Gain (Loss) Recognized in Net Periodic Benefit Cost, before Tax	[1]	100.9	73.8	303.1	222.4
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, before Tax		81.8	67.3	245.9	203.1
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Tax		(27)	(22.6)	(83)	(66.1)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net (Gain) Loss, Net of Tax		54.8	44.7	162.9	137
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax		(149.5)	(91.6)	(213.9)	(241.1)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax		(145)	(91.6)	(203.2)	(241.1)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax		50.7	32.1	71.1	84.4
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax		(94.3)	(59.5)	(132.1)	(156.7)
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, before Tax		(4.5)	0	(10.7)	0
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax		(59.6)	(22.8)	(48.2)	(66.3)
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, before Reclassification Adjustments, Tax		31.1	30.8	93.9	70.8
Other Comprehensive Income, Other, Net of Tax		2.4	14.6	7.1	61.1
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax		1.3	(10.7)	(15.9)	19.9
Other Comprehensive Income (Loss), Tax		(33.1)	(2.7)	12.1	24.4
Accumulated Translation Adjustment [Member]
Accumulated other comprehensive loss		(1,264.3)	(167.5)	(1,264.3)	(167.5)	(1,037.6)	(498.4)	467.9	463
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		(226.7)	(635.4)	(765.9)	(630.5)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax		0	0	0	0
Other comprehensive loss, net of tax		(226.7)	(635.4)	(765.9)	(630.5)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated other comprehensive loss		10.5	82.5	10.5	82.5	121	99.7	124.7	205.2
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		(16.2)	17.3	42.9	34
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax		(94.3)	(59.5)	(132.1)	(156.7)
Other comprehensive loss, net of tax		(110.5)	(42.2)	(89.2)	(122.7)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated other comprehensive loss		(3,192.3)	(2,322.1)	(3,192.3)	(2,322.1)	(3,263.3)	(3,402)	(2,403.3)	(2,489.1)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		16.2	36.5	46.8	30
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax		54.8	44.7	162.9	137
Other comprehensive loss, net of tax		71	81.2	209.7	167
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated other comprehensive loss		(220.9)	(144.5)	(220.9)	(144.5)	$ (223.3)	$ (191.1)	$ (124.6)	$ (181.8)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		0	(34.5)	(36.9)	(23.8)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment Realized upon Sale or Liquidation, Net of Tax		2.4	14.6	7.1	61.1
Other comprehensive loss, net of tax		$ 2.4	$ (19.9)	$ (29.8)	$ 37.3
[1]	(1) These accumulated other comprehensive loss components are included in the computation of net periodic benefit (see Note 10).

Other - Net, (Income) Expense42

Other - Net, (Income) Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Interest Expense	$ 39.3	$ 38.1	$ 117	$ 111.4
Investment Income, Interest	(21.2)	(28.8)	(63.2)	(96.8)
Debt extinguishment loss	0	0	166.7	0
Other (income)expense	(104.6)	(102.8)	(276.4)	(217.9)
Nonoperating Income (Expense), Total	$ (86.5)	$ (93.5)	$ (55.9)	$ (203.3)

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue		$ 4,959.7	$ 4,875.6	$ 14,583.1	$ 14,494.3
Collaboration and other revenue		215.2	204	644.7	593.9
Income before income taxes		1,047.8	655.5	2,345.4	2,486.7
Acquired in-process research and development		0	(95)	(336)	(95)
Asset impairment, restructuring, and other special charges		(42.4)	(36.3)	(222.8)	(67.7)
Nonoperating Income (Expense)		86.5	93.5	55.9	203.3
Amortization of Intangible Assets		(154.1)	(134)	(461.7)	(399.9)
Cost of sales		(1,236.9)	(1,267)	(3,648)	(3,679.4)
Marketing, selling, and administrative		(1,575.7)	(1,672.1)	(4,734.6)	(4,820.9)
Debt extinguishment loss		0	0	166.7	0
Neuroscience [Member]
Revenue		724.5	869.9	2,213.6	2,727.9
Endocrinology [Member]
Revenue		1,786.4	1,708.3	5,050.6	5,087
Oncology [Member]
Revenue		861.3	882.4	2,542.8	2,505.1
Cardiovascular [Member]
Revenue		759.9	757.2	2,238.3	2,235.3
Animal Health [Member]
Income before income taxes		139.8	145.8	443.1	417.6
Other pharmaceuticals [Member]
Revenue		48.8	73.1	168.5	225.7
Pharmaceutical products, total [Member]
Revenue		4,180.9	4,290.9	12,213.8	12,781
Income before income taxes		1,124.1	760	3,224	2,350.8
Amortization of Intangible Assets			(118.9)		(352.4)
Animal Health Products [Member]
Revenue		778.8	584.7	2,369.3	1,713.3
Amortization of Intangible Assets			(15.7)		(43.1)
Operating Segments [Member]
Income before income taxes		1,263.9	905.8	3,667.1	2,768.4
Corporate, Non-Segment [Member]
Acquired in-process research and development		0	(95)	(336)	(95)
Asset impairment, restructuring, and other special charges		(42.4)	(36.3)	(222.8)	(67.7)
Amortization of Intangible Assets	[1]	(152.5)	0	(457.2)	0
Marketing, selling, and administrative		0	(119)	0	(119)
Other Endocrinology [Member] | Endocrinology [Member]
Revenue		191.4	165.7	512.4	491.3
Humalog [Member] | Endocrinology [Member]
Revenue		705	706.1	2,043.3	2,056.1
Humulin [Member] | Endocrinology [Member]
Revenue		316.7	335.9	948.8	1,004.5
Forteo [Member] | Endocrinology [Member]
Revenue		348.9	332.2	970.4	941.2
Evista [Member] | Endocrinology [Member]
Revenue		58	89.5	184.5	347.8
Trulicity [Member] [Member] | Endocrinology [Member]
Revenue		73.7	0	136.2	0
Trajenta (BI) [Member]
Collaboration and other revenue			78.9		246.1
Trajenta (BI) [Member] | Endocrinology [Member]
Collaboration and other revenue		92.7	78.9	255	246.1
Cymbalta [Member] | Neuroscience [Member]
Revenue		242.9	368	804	1,247.5
Zyprexa [Member] | Neuroscience [Member]
Revenue		237.9	257.4	711.2	784.2
Strattera [Member] | Neuroscience [Member]
Revenue		196.9	191.9	562.4	543.7
Other Neuroscience [Member] | Neuroscience [Member]
Revenue		46.8	52.6	136	152.5
Alimta [Member] | Oncology [Member]
Revenue		628.5	723.4	1,865.8	2,067
Erbitux [Member]
Revenue		85.9	92.9	308.8	277.3
Collaboration and other revenue		88.2	84.1	286.2	242.8
Erbitux [Member] | Oncology [Member]
Revenue		85.9	92.9	308.8	277.3
Other Oncology [Member] | Oncology [Member]
Revenue		35.7	37.7	101.8	118.8
Cialis [Member] | Cardiovascular [Member]
Revenue		566.1	568.4	1,672.3	1,668.6
Effient [Member]
Revenue		132.1	131.5	382.7	384.4
Effient [Member] | Cardiovascular [Member]
Revenue		132.1	131.5		384.4
Other Cardiovascular [Member] | Cardiovascular [Member]
Revenue		61.7	57.3	183.3	182.3
Cyramza [Member] | Oncology [Member]
Revenue		111.2	28.4	266.4	42
Fair Value Adjustment to Inventory [Member] | Corporate, Non-Segment [Member]
Cost of sales		(21.2)	0	(153)	0
Long-term Debt [Member] | Corporate, Non-Segment [Member]
Nonoperating Income (Expense)	[2]	$ 0	$ 0	$ (152.7)	$ 0
[1]	(1) In 2015, the measurement of segment profitability was changed to exclude the amortization of intangible assets. If we were to adjust the three months ended September 30, 2014 to conform with the 2015 presentation and exclude amortization of intangible assets, the human pharmaceutical and animal health segment profits would be increased by $118.9 million and $15.7 million, respectively, and $352.4 million and $43.1 million for the nine months ended September 30, 2014, respectively.
[2]	(2) We recognized pretax net charges of $152.7 million for the nine months ended September 30, 2015, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the related issuance of euro-denominated notes.